/
bibliography.bib
8345 lines (7731 loc) · 960 KB
/
bibliography.bib
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
@article{barrettNeurodegenerationDiabetesUK1995,
title = {Neurodegeneration and Diabetes: {{UK}} Nationwide Study of {{Wolfram}} ({{DIDMOAD}}) Syndrome},
volume = {346},
journal = {The Lancet},
author = {Barrett, Timothy and Bundey, Sarah and Macleod, Andrew},
year = {1995},
keywords = {Wolfram},
pages = {1458--63},
file = {/Users/k/Zotero/storage/NTBRR43Z/Barrett, Bundey, Macleod - 1995 - Neurodegeneration and diabetes UK nationwide study of Wolfram (DIDMOAD) syndrome.pdf;/Users/k/Zotero/storage/X4RVSFCZ/Barrett, Bundey, Macleod - 1995 - Neurodegeneration and diabetes UK nationwide study of Wolfram (DIDMOAD) syndrome.pdf}
}
@misc{centerforhistoryandnewmediaZoteroQuickStart,
title = {Zotero {{Quick Start Guide}}},
howpublished = {http://zotero.org/support/quick\_start\_guide},
author = {{Center for History and New Media}}
}
@misc{harrellBayesianVsFrequentist2017,
title = {Bayesian vs. {{Frequentist Statements About Treatment Efficacy}}},
abstract = {To avoid ``false positives'' do away with ``positive''.
A good poker player plays the odds by thinking to herself ``The probability I can win with this hand is 0.91'' and not ``I'm going to win this game'' when deciding the next move.
State conclusions honestly, completely deferring judgments and actions to the ultimate decision makers. Just as it is better to make predictions than classifications in prognosis and diagnosis, use the word ``probably'' liberally, and avoid thinking ``the evidence against the null hypothesis is strong, so we conclude the treatment works'' which creates the opportunity of a false positive.},
language = {en-us},
journal = {Statistical Thinking},
howpublished = {http://fharrell.com/post/bayes-freq-stmts/},
author = {Harrell, Frank},
month = oct,
year = {2017},
file = {/Users/k/Zotero/storage/UNEZ7BGF/bayes-freq-stmts.html}
}
@misc{harrellMusingsMultipleEndpoints2018,
title = {Musings on {{Multiple Endpoints}} in {{RCTs}}},
abstract = {Learning is more productive than avoiding mistakes. And if one wishes to just avoid mistakes, make sure the mistakes are real. Question whether labeling endpoints is productive, and whether type I error risks are valuable in quantifying evidence for effects and should interfere with asking questions. The NHLBI-funded ISCHEMIA multinational randomized clinical trial1 is designed to assess the effect of cardiac catheterization-guided coronary revascularization strategy (which includes optimal medical management) compared to optimal medical management alone (with cardiac cath reserved for failure of medical therapy) for patients with stable coronary artery disease.},
language = {en-us},
journal = {Statistical Thinking},
howpublished = {http://fharrell.com/post/ymult/},
author = {Harrell, Frank},
month = mar,
year = {2018},
file = {/Users/k/Zotero/storage/4HMEN4CM/ymult.html}
}
@misc{harrellStatisticalErrorsMedical,
title = {Statistical {{Errors}} in the {{Medical Literature}}},
abstract = {Misinterpretation of P-values and Main Study Results Dichotomania Problems With Change Scores Improper Subgrouping Serial Data and Resp...},
author = {Harrell, Frank},
keywords = {BeBetterStatistician},
file = {/Users/k/Zotero/storage/XVGACI2J/statistical-errors-in-medical-literature.html}
}
@misc{PembrolizumabNotNivolumab,
title = {Pembrolizumab, but {{Not Nivolumab}}, {{Improves Outcomes}} in {{Front}}-{{Line Setting}} for {{PD}}-{{L1}}\textendash{{Positive Advanced NSCLC}} - {{The ASCO Post}}},
howpublished = {http://www.ascopost.com/issues/november-10-2016/pembrolizumab-but-not-nivolumab-improves-outcomes-in-front-line-setting-for-pd-l1-positive-advanced-nsclc/},
file = {/Users/k/Zotero/storage/NSWMNXVX/pembrolizumab-but-not-nivolumab-improves-outcomes-in-front-line-setting-for-pd-l1-positive-adva.html}
}
@article{vejbaesyaNIHPublicAccess2010,
title = {{{NIH Public Access}}},
volume = {199},
issn = {1946-6242},
doi = {10.1086/597422.Tumor},
number = {2},
author = {Vejbaesya, Sasijit and Luangtrakool, Panpimon and Luangtrakool, Komon and Vaughn, David W and Endy, Timothy P and Mammen, Mammen P and Libraty, Daniel H and Ennis, Francis A and Rothman, Alan L and Henry, A F},
year = {2010},
keywords = {Corneal,33447,44-207-794-0500 ext 35123 or,address correspondence to dr,centre for nephrology and,dengue,disease severity,e-mail,ethnic thais,genetic associations,henry stephens,hla,london nw3 2pf,lta,rowland hill street,royal free hospital campus,tel,the,the anthony nolan trust,tnf,uk,university college london},
pages = {1442--1448},
pmid = {20371490}
}
@article{millsDesignAnalysisPresentation2009,
title = {Design, Analysis, and Presentation of Crossover Trials.},
volume = {10},
issn = {1745-6215},
doi = {10.1186/1745-6215-10-27},
abstract = {OBJECTIVE: Although crossover trials enjoy wide use, standards for analysis and reporting have not been established. We reviewed methodological aspects and quality of reporting in a representative sample of published crossover trials. METHODS: We searched MEDLINE for December 2000 and identified all randomized crossover trials. We abstracted data independently, in duplicate, on 14 design criteria, 13 analysis criteria, and 14 criteria assessing the data presentation. RESULTS: We identified 526 randomized controlled trials, of which 116 were crossover trials. Trials were drug efficacy (48\%), pharmacokinetic (28\%), and nonpharmacologic (30\%). The median sample size was 15 (interquartile range 8-38). Most (72\%) trials used 2 treatments and had 2 periods (64\%). Few trials reported allocation concealment (17\%) or sequence generation (7\%). Only 20\% of trials reported a sample size calculation and only 31\% of these considered pairing of data in the calculation. Carry-over issues were addressed in 29\% of trial's methods. Most trials reported and defended a washout period (70\%). Almost all trials (93\%) tested for treatment effects using paired data and also presented details on by-group results (95\%). Only 29\% presented CIs or SE so that data could be entered into a meta-analysis. CONCLUSION: Reports of crossover trials frequently omit important methodological issues in design, analysis, and presentation. Guidelines for the conduct and reporting of crossover trials might improve the conduct and reporting of studies using this important trial design.},
journal = {Trials},
author = {Mills, Edward J and Chan, An-Wen and Wu, Ping and Vail, Andy and Guyatt, Gordon H and Altman, Douglas G},
year = {2009},
keywords = {CrossoverTrials},
pages = {27},
file = {/Users/k/Zotero/storage/2YU9E8GH/Mills et al. - 2009 - Design, analysis, and presentation of crossover trials.pdf;/Users/k/Zotero/storage/RFC292X3/Mills et al. - 2009 - Design, analysis, and presentation of crossover trials.pdf},
pmid = {19405975}
}
@article{heHHSPublicAccess2015,
title = {{{HHS Public Access}}},
volume = {33},
issn = {1527-5418},
number = {4},
author = {He, Qiye and Johnston, Jeff and Zeitlinger, Julia and City, Kansas and City, Kansas},
year = {2015},
pages = {395--401},
pmid = {24655651}
}
@misc{BayesianInferenceCompletely2016,
title = {Bayesian Inference Completely Solves the Multiple Comparisons Problem},
abstract = {I promised I wouldn't do any new blogging until January but I'm here at this conference and someone asked me a question about the above slide from my talk. The point of the story in that slide is that flat priors consistently give bad inferences. Or, to put it another way, the routine use of \ldots{}},
language = {en-US},
journal = {Statistical Modeling, Causal Inference, and Social Science},
howpublished = {http://andrewgelman.com/2016/08/22/bayesian-inference-completely-solves-the-multiple-comparisons-problem/},
month = aug,
year = {2016},
file = {/Users/k/Zotero/storage/NRKM3N8M/bayesian-inference-completely-solves-the-multiple-comparisons-problem.html}
}
@article{Lilenbaum2008,
title = {Randomized Phase {{II}} Trial of Erlotinib or Standard Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer and a Performance Status of 2.},
volume = {26},
issn = {1527-7755},
doi = {10.1200/JCO.2007.13.2720},
abstract = {PURPOSE: A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line management of advanced non-small-cell lung cancer (NSCLC) patients with a performance status (PS) of 2. PATIENTS AND METHODS: Patients were assigned to erlotinib 150 mg orally daily until progression or to carboplatin (area under the curve [AUC] 6) and paclitaxel (200 mg/m(2) day 1 every 3 weeks) for up to four cycles. Patients who experienced progression or did not tolerate or refused further chemotherapy were allowed to cross over to erlotinib. The primary end point was progression-free survival (PFS). Secondary end points were response, survival, quality of life (QOL), and a retrospective molecular correlation. RESULTS: Fifty-two patients were randomly assigned to erlotinib and 51 to chemotherapy. Partial responses were 2\% and 12\%, respectively. Median PFS was 1.9 months in the erlotinib arm and 3.5 months in the chemotherapy arm (hazard ratio [HR] = 1.45; 95\% CI, 0.98 to 2.15; P = .06). Median survival times were 6.5 and 9.7 months, respectively (HR = 1.73; 95\% CI, 1.09 to 2.73; P = .018). Patients who crossed over to erlotinib had a median survival of 14.9 months. Sex, histology, skin rash, and smoking history predicted outcome with erlotinib. Rash and diarrhea were more common with erlotinib; emesis, alopecia, peripheral neuropathy, and fatigue were more common with chemotherapy. QOL was similar between the two arms. Molecular correlation was limited by available samples. CONCLUSION: Unselected patients with advanced NSCLC and PS 2 are best treated with combination chemotherapy as first-line therapy. Erlotinib may be considered in patients selected by clinical or molecular markers.},
number = {6},
journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
author = {Lilenbaum, Rogerio and Axelrod, Rita and Thomas, Sachdev and Dowlati, Afshin and Seigel, Leonard and Albert, Donald and Witt, Karsten and Botkin, David},
year = {2008},
keywords = {NSCLC},
pages = {863-869},
file = {/Users/k/Zotero/storage/CUBJXU4C/Lilenbaum et al. - 2008 - Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung.pdf;/Users/k/Zotero/storage/JMHUP3PU/Lilenbaum et al. - 2008 - Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung.pdf},
pmid = {18281658}
}
@article{Lilenbaum2005,
title = {Single-Agent versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: {{The Cancer}} and {{Leukemia Group B}} (Study 9730)},
volume = {23},
issn = {0732183X},
doi = {10.1200/JCO.2005.07.172},
abstract = {We compared the efficacy of combination chemotherapy versus single-agent therapy in patients with advanced non-small-cell lung cancer.},
number = {1},
journal = {Journal of Clinical Oncology},
author = {Lilenbaum, Rogerio C. and Herndon, James E. and a. List, Marcy and Desch, Chris and Watson, Dorothy M. and a. Miller, Antonius and Graziano, Stephen L. and Perry, Michael C. and Saville, Wayne and Chahinian, Philippe and Weeks, Jane C. and Holland, Jimmie C. and Green, Mark R.},
year = {2005},
keywords = {NSCLC,PS2},
pages = {190-196},
file = {/Users/k/Zotero/storage/GP3ZXSEC/Lilenbaum et al. - 2005 - Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer The Cancer and Leukemia Gr.pdf},
pmid = {15625373}
}
@article{Smith2015,
title = {Early Experience of the Use of Fibrin Sealant in the Management of Children with Pilonidal Sinus Disease.},
volume = {50},
issn = {1531-5037},
doi = {10.1016/j.jpedsurg.2014.11.022},
abstract = {BACKGROUND: The use of fibrin sealant in the management of pilonidal sinus disease has not previously been described in children. We present our experience of primary pit excision and use of fibrin sealant (PEF) and compare outcomes with lateralising flap procedures (LFP).$\backslash$n$\backslash$nMETHODS: A single centre retrospective case note review of all children who had undergone a definitive procedure for pilonidal sinus from August 2006 to Dec 2013 was performed using data expressed as median (range) and compared using Fisher's exact test. P$<$0.05 was regarded as significant.$\backslash$n$\backslash$nRESULTS: Forty-one children were identified having undergone 49 procedures, with median age 15 (12-16 years) and follow up 32 (8-92) months. Groups were comparable for disease severity. Ten children underwent primary PEF and twenty-six LFP. Two children had recurrence following primary PEF and had repeat PEF which was curative. Overall recurrence rates following PEF procedure were comparable to LFP (17\% vs 21\%; P=1.0). There were no wound dehiscences in the PEF group and one wound infection. There was one wound dehiscence and one wound infection in the LFP group. Median operative time for PEF was lower than LFP (20 vs 60 min, P=0.001). 83\% of PEF procedures were performed as day cases. One child was lost to follow up, and two children progressed to adult services.$\backslash$n$\backslash$nCONCLUSIONS: We recommend PEF in children with pilonidal sinus disease as primary treatment and for recurrence. PEF has comparable recurrence and wound infection rates to LFPs, is performed as day case, has shorter anaesthetic times, and the risk of wound dehiscence is avoided.},
number = {2},
journal = {Journal of pediatric surgery},
author = {Smith, Caroline Mary and Jones, Abigail and Dass, Dipankar and Murthi, Govind and Lindley, Richard},
year = {2015},
keywords = {Surgery,Fibrin,Fibrin glue,Fibrin sealant,Pilonidal,Pilonidal disease,Pilonidal sinus},
pages = {320-2},
file = {/Users/k/Zotero/storage/76KASK4U/Smith et al. - 2015 - Early experience of the use of fibrin sealant in the management of children with pilonidal sinus disease.pdf;/Users/k/Zotero/storage/HE4RLRM7/Smith et al. - 2015 - Early experience of the use of fibrin sealant in the management of children with pilonidal sinus disease.pdf},
pmid = {25638628}
}
@article{Handmer2012,
title = {Sticking to the Facts: A Systematic Review of Fibrin Glue for Pilonidal Disease},
volume = {82},
issn = {1445-2197; 1445-1433},
doi = {http://dx.doi.org/10.1111/j.1445-2197.2011.05752.x},
abstract = {BACKGROUND: Pilonidal disease occurs when hair invading the natal cleft causes inflammation and abscess formation. Opinions vary on best practice, and most procedures have considerable morbidity and high recurrence rates of 6-40\%. OBJECTIVES: This study systematically reviews the use of fibrin glue in the treatment of pilonidal disease. Outcomes measured were healing time and recurrence rate. DATA SOURCE: ScienceDirect and PubMed databases were searched for relevant literature, yielding seven papers including five small trials. The total number of patients receiving fibrin glue treatments across all trials was 85. There were no exclusion criteria in this review. RESULTS: Fibrin glue treatments had equivalent or better reported healing times than conventional therapies at an average of 2-6 weeks, and low recurrence rates between 0 and 17\% at follow-up periods between 4 and 28 months. Considerable heterogeneity in study methodologies and surgical techniques prevented statistical significance or aggregate figures from being determined. CONCLUSIONS: There appears to be early promise for the use of fibrin glue in the treatment of pilonidal disease and an impetus for definitive research.Copyright 2011 The Author. ANZ Journal of Surgery 2011 Royal Australasian College of Surgeons.},
number = {4},
journal = {ANZ Journal of Surgery},
author = {Handmer, M},
year = {2012},
keywords = {Humans,Surgery,Fibrin,Pilonidal,Fibrin Tissue Adhesive/tu [Therapeutic Use],Index Medicus,Pilonidal Sinus/su [Surgery],Tissue Adhesives/tu [Therapeutic Use],Wound Healing},
pages = {221-224},
file = {/Users/k/Zotero/storage/HESHPMPH/Handmer - 2012 - Sticking to the facts a systematic review of fibrin glue for pilonidal disease.pdf;/Users/k/Zotero/storage/LN85LHWY/Handmer - 2012 - Sticking to the facts a systematic review of fibrin glue for pilonidal disease.pdf},
pmid = {22510177}
}
@article{McCulloch2009,
title = {No Surgical Innovation without Evaluation: The {{IDEAL}} Recommendations},
volume = {374},
issn = {01406736},
doi = {10.1016/S0140-6736(09)61116-8},
abstract = {Surgery and other invasive therapies are complex interventions, the assessment of which is challenged by factors that depend on operator, team, and setting, such as learning curves, quality variations, and perception of equipoise. We propose recommendations for the assessment of surgery based on a five-stage description of the surgical development process. We also encourage the widespread use of prospective databases and registries. Reports of new techniques should be registered as a professional duty, anonymously if necessary when outcomes are adverse. Case series studies should be replaced by prospective development studies for early technical modifications and by prospective research databases for later pre-trial evaluation. Protocols for these studies should be registered publicly. Statistical process control techniques can be useful in both early and late assessment. Randomised trials should be used whenever possible to investigate efficacy, but adequate pre-trial data are essential to allow power calculations, clarify the definition and indications of the intervention, and develop quality measures. Difficulties in doing randomised clinical trials should be addressed by measures to evaluate learning curves and alleviate equipoise problems. Alternative prospective designs, such as interrupted time series studies, should be used when randomised trials are not feasible. Established procedures should be monitored with prospective databases to analyse outcome variations and to identify late and rare events. Achievement of improved design, conduct, and reporting of surgical research will need concerted action by editors, funders of health care and research, regulatory bodies, and professional societies. \textcopyright{} 2009 Elsevier Ltd. All rights reserved.},
number = {9695},
journal = {The Lancet},
author = {McCulloch, Peter and Altman, Douglas G. and Campbell, W. Bruce and Flum, David R. and Glasziou, Paul and Marshall, John C. and Nicholl, Jon},
year = {2009},
keywords = {Surgery,3,evaluation,no surgical innovation without,surgical innovation and evaluation,the ideal,IDEAL},
pages = {1105-1112},
file = {/Users/k/Zotero/storage/27FGJTQA/McCulloch et al. - 2009 - No surgical innovation without evaluation the IDEAL recommendations.pdf;/Users/k/Zotero/storage/3SR8FASW/McCulloch et al. - 2009 - No surgical innovation without evaluation the IDEAL recommendations.pdf},
pmid = {19782876}
}
@article{jamesAdditionDocetaxelZoledronic2015,
title = {Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer ({{STAMPEDE}}): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial},
doi = {10.1016/S0140-6736(15)01037-5},
abstract = {Articles www.thelancet.com Published online December 21, 2015 http://dx.doi.org/10.1016/S0140-6736(15)01037-5 1 Addition of docetaxel, zoledronic acid, or both to fi rst-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting fi rst-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.},
author = {James, Nicholas D and Sydes, Matthew R and Clarke, Noel W and Mason, Malcolm D and Dearnaley, David P and Spears, Melissa R and Ritchie, Alastair W S and Parker, Christopher C and Russell, J Martin and Attard, Gerhardt and De Bono, Johann and Cross, William and Jones, Rob J and Thalmann, George and Amos, Claire and Matheson, David and Millman, Robin and Alzouebi, Mymoona and Beesley, Sharon and Birtle, Alison J and Brock, Susannah and Cathomas, Richard and Chakraborti, Prabir and Chowdhury, Simon and Cook, Audrey and Elliott, Tony and Gale, Joanna and Gibbs, Stephanie and Graham, John D and Hetherington, John and Hughes, Robert and Laing, Robert and Mckinna, Fiona and Mclaren, Duncan B and O 'sullivan, Joe M and Parikh, Omi and Peedell, Clive and Protheroe, Andrew and Robinson, Angus J and Srihari, Narayanan and Srinivasan, Rajaguru and Staff, John and Sundar, Santhanam and Tolan, Shaun and Tsang, David and Wagstaff, John and Parmar, Mahesh K B},
year = {2015},
keywords = {MAMS},
file = {/Users/k/Zotero/storage/F72ZYXGT/James et al. - 2015 - Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPE.pdf}
}
@article{Monahan1997,
title = {Spherical-{{Radial Integration Rules}} for {{Bayesian Computation}}},
volume = {92},
number = {438},
journal = {Journal of the American Statistical Association},
author = {Monahan, John and Genz, Alan},
year = {1997},
keywords = {importance,monte carlo,NumericalIntegration,randomized numerical},
pages = {664-674},
file = {/Users/k/Zotero/storage/2AHS3Z24/Monahan, Genz - 1997 - Spherical-Radial Integration Rules for Bayesian Computation.pdf}
}
@article{Ludbrook2013,
title = {Should We Use One-Sided or Two-Sided {{P}} Values in Tests of Significance?},
volume = {40},
issn = {03051870},
doi = {10.1111/1440-1681.12086},
number = {6},
journal = {Clinical and Experimental Pharmacology and Physiology},
author = {Ludbrook, John},
year = {2013},
keywords = {11,and new zealand,con fi dence interval,fisher,from a google scholar,google scholar,journal of surgery over,lehmann,neyman,p values were used,pearson,search of the australian,Stats,the decade 2002,type iii error},
pages = {357-361},
file = {/Users/k/Zotero/storage/VVZGCIGA/Ludbrook - 2013 - Should we use one-sided or two-sided P values in tests of significance.pdf;/Users/k/Zotero/storage/YXL92RCP/Ludbrook - 2013 - Should we use one-sided or two-sided P values in tests of significance.pdf}
}
@article{Zukin2013,
title = {Randomized Phase {{III}} Trial of Single-Agent Pemetrexed versus Carboplatin and Pemetrexed in Patients with Advanced Non-Small-Cell Lung Cancer and {{Eastern Cooperative Oncology Group}} Performance Status of 2},
volume = {31},
issn = {0732183X},
doi = {10.1200/JCO.2012.48.1911},
abstract = {PURPOSETo compare single-agent pemetrexed (P) versus the combination of carboplatin and pemetrexed (CP) in first-line therapy for patients with advanced non-small-cell lung cancer (NSCLC) with an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. PATIENTS AND METHODSIn a multicenter phase III randomized trial, patients with advanced NSCLC, ECOG PS of 2, any histology at first and later amended to nonsquamous only, no prior chemotherapy, and adequate organ function were randomly assigned to P alone (500 mg/m(2)) or CP (area under the curve of 5 and 500 mg/m(2), respectively) administered every 3 weeks for a total of four cycles. The primary end point was overall survival (OS).ResultsA total of 205 eligible patients were enrolled from eight centers in Brazil and one in the United States from April 2008 to July 2011. The response rates were 10.3\% for P and 23.8\% for CP (P = .032). In the intent-to-treat population, the median PFS was 2.8 months for P and 5.8 months for CP (hazard ratio [HR], 0.46; 95\% CI, 0.35 to 0.63; P $<$ .001), and the median OS was 5.3 months for P and 9.3 months for CP (HR, 0.62; 95\% CI, 0.46 to 0.83; P = .001). One-year survival rates were 21.9\% and 40.1\%, respectively. Similar results were seen when patients with squamous disease were excluded from the analysis. Anemia (grade 3, 3.9\%; grade 4, 11.7\%) and neutropenia (grade 3, 1\%; grade 4, 6.8\%) were more frequent with CP. There were four treatment-related deaths in the CP arm. CONCLUSIONCombination chemotherapy with CP significantly improves survival in patients with advanced NSCLC and ECOG PS of 2.},
number = {23},
journal = {Journal of Clinical Oncology},
author = {Zukin, Mauro and Barrios, Carlos H. and Pereira, Jose Rodrigues and Ribeiro, Ronaldo De Albuquerque and Beato, Carlos Augusto De Mendon{\c c}a and Do Nascimento, Yeni Neron and Murad, Andre and a. Franke, Fabio and Precivale, Maristela and Araujo, Luiz Henrique De Lima and Baldotto, Clarissa Serodio Da Rocha and Vieira, Fernando Meton and a. Small, Isabele and Ferreira, Carlos G. and Lilenbaum, Rogerio C.},
year = {2013},
keywords = {NSCLC,PS2},
pages = {2849-2853},
file = {/Users/k/Zotero/storage/KDVA8PE3/Zukin et al. - 2013 - Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced.pdf;/Users/k/Zotero/storage/MECX83RZ/Zukin et al. - 2013 - Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanc(2).pdf;/Users/k/Zotero/storage/TD5ITQVK/Zukin et al. - 2013 - Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced.pdf},
pmid = {23775961}
}
@article{Bosch2015,
title = {Ibrutinib in {{CLL}}: 2 Sides of the Same Coin},
volume = {126},
issn = {0006-4971},
doi = {10.1182/blood-2015-09-670653},
number = {19},
journal = {Blood},
author = {Bosch, F. and Abrisqueta, P.},
year = {2015},
keywords = {CLL,Ibrutinib},
pages = {2173-2174},
file = {/Users/k/Zotero/storage/BIPVT3VU/Bosch, Abrisqueta - 2015 - Ibrutinib in CLL 2 sides of the same coin.pdf;/Users/k/Zotero/storage/MEMDEG7U/Bosch, Abrisqueta - 2015 - Ibrutinib in CLL 2 sides of the same coin.pdf},
pmid = {26542251}
}
@article{Antoniou2015a,
title = {Evaluating {{Statistical Characteristics}} of {{Biomarker}}-{{Guided Trial Designs Personalized Medicine}}},
author = {Antoniou, Miranta},
year = {2015},
keywords = {Biomarkers,biomarkers},
file = {/Users/k/Zotero/storage/CS6RQBCX/Antoniou - 2015 - Evaluating Statistical Characteristics of Biomarker-Guided Trial Designs Personalized Medicine.pdf;/Users/k/Zotero/storage/U2MUNSSK/Antoniou - 2015 - Evaluating Statistical Characteristics of Biomarker-Guided Trial Designs Personalized Medicine.pdf;/Users/k/Zotero/storage/ZWMBM989/Antoniou - 2015 - Evaluating Statistical Characteristics of Biomarker-Guided Trial Designs Personalized Medicine.pdf}
}
@article{Buyse2013,
title = {Omics-Based Clinical Trial Designs},
issn = {1040-8746},
doi = {10.1097/CCO.0b013e32835ff2fe},
journal = {Current Opinion in Oncology},
author = {Buyse, Marc and Michiels, Stefan},
year = {2013},
keywords = {predictive biomarker,Genomics,clinical trials,prognostic biomarker,signature,genomics},
pages = {1},
file = {/Users/k/Zotero/storage/3UH2KAJD/Buyse, Michiels - 2013 - Omics-based clinical trial designs.pdf;/Users/k/Zotero/storage/R7PD9WPX/Buyse, Michiels - 2013 - Omics-based clinical trial designs.pdf}
}
@article{Hayes2015,
title = {Lessons for Tumor Biomarker Trials: Vicious Cycles, Scientific Method \& Developing Guidelines.},
volume = {15},
issn = {1744-8352 (Electronic)},
doi = {10.1586/14737159.2015.991893},
abstract = {Interview with Daniel Hayes, by Claire Raison (Commissioning Editor) Daniel F Hayes, M.D. is the Stuart A Padnos Professor of Breast Cancer Research and co-Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center (Ann Arbor, MI, USA). Dr Hayes has extensive experience in clinical and translational breast cancer biomarker research, and in drug development and clinical trials. Around 30 years ago, he led the discovery of the circulating breast tumor biomarker, CA15-3, which started his career into further tumor biomarker work. The main thrust of his work since then has been in clinical trials, tumor biomarkers and trying to integrate the two. Dr Hayes is Chair of the Correlative Sciences Committee of the North American Breast Cancer Group (now called the Breast Cancer Steering Committee), and co-chairs the Expert Panel for Tumor Biomarker Practice Guidelines for the American Society of Clinical Oncology.},
number = {2},
journal = {Expert review of molecular diagnostics},
author = {Hayes, Daniel and Raison, Claire},
year = {2015},
keywords = {Biomarkers,biomarkers},
pages = {165-169},
file = {/Users/k/Zotero/storage/QE9EMNMS/Hayes, Raison - 2015 - Lessons for tumor biomarker trials vicious cycles, scientific method & developing guidelines.pdf},
pmid = {25548983}
}
@article{Buyse2011,
title = {Integrating Biomarkers in Clinical Trials},
volume = {11},
issn = {1473-7159},
doi = {10.1586/ERM.10.120},
abstract = {Clinical trials have revolutionized medicine by providing reliable evidence on the efficacy and safety of new treatments. Until recently, clini-cal trials were designed and analyzed under the assumption that the effects of treatment were broadly similar in different individuals, and hence the goal of the clinical trial was primar-ily to provide precise and unbiased estimates of these common effects. Today, the advent of molecular biology has modified the funda mental tenet that the effect of treatment varies only ran-domly from patient to patient. There are indeed increasing numbers of treatments (especially targeted agents) whose effects vary widely as a function of individual molecular characteristics. When these characteristics are known early on in the course of developing of new treatments, clinical trials can be designed to target only those patients who are expected to benefit. However, more commonly, the exact molecular character-istics that drive a patient's response to a specific treatment are unknown and might only be dis-covered during the clinical development of the treatment or indeed following its approval. This fact has profound implications for clinical trials; it may indeed revolutionize the way in which tri-als are planned and executed [1\textendash{}3]. The purposes of this article are, first, to discuss the ways in which biomarkers (including, but not limited to, molecular characteristics) are validated in clini-cal trials, and second, to consider how they can be incorporated into clinical trial designs with the goal of optimizing the use of new therapies in biomarker-defined subgroups of patients. Our examples all come from the field of oncology, where efforts to develop new methodologies for clinical research have been most intense, but fur-ther examples abound in the other therapeutic areas [4]. We will focus our discussion on statisti-cal issues, leaving aside practical considerations related to the bio markers themselves, such as their accessibility in specific tissues (e.g., in fresh, frozen or formalin-fixed paraffin-embedded tis-sue) or the ease and reliability of their quantifica-tion (e.g., through reverse-transcriptase PCR or microarray), all of which greatly contribute to their potential for use in clinical practice.},
number = {2},
journal = {Expert Review of Molecular Diagnostics2},
author = {Buyse, Marc and Michiels, Stefan and Sargent, Daniel J and Grothey, Axel and Matheson, Alastair and {de Gramont}, Aimery},
year = {2011},
keywords = {Biomarkers,biomarkers},
pages = {171-182},
file = {/Users/k/Zotero/storage/FDM5RJEU/Buyse et al. - 2011 - Integrating biomarkers in clinical trials.pdf}
}
@article{Middleton2015,
title = {The {{National Lung Matrix Trial}}: Translating the Biology of Stratification in Advanced Non-Small-Cell Lung Cancer},
issn = {0923-7534},
doi = {10.1093/annonc/mdv394},
journal = {Annals of Oncology},
author = {Middleton, G. and Crack, L. R. and Popat, S. and Swanton, C. and Hollingsworth, S. J. and Buller, R. and Walker, I. and Carr, T. H. and Wherton, D. and Billingham, L. J.},
year = {2015},
keywords = {Adaptive trial design,National Lung Matrix Trial,Non-small-cell lung cancer,Stratified medicine,Umbrella Trial,strati fi ed medicine,adaptive trial design,national lung matrix trial,non-small-cell lung cancer,umbrella trial},
pages = {mdv394},
file = {/Users/k/Zotero/storage/29F6VGDM/Middleton et al. - 2015 - The National Lung Matrix Trial translating the biology of stratification in advanced non-small-cell lung cance.pdf;/Users/k/Zotero/storage/9469VFLQ/Middleton et al. - 2015 - The National Lung Matrix Trial Translating the biology of stratification in advanced non-small-cell lung ca(2).pdf;/Users/k/Zotero/storage/NZTDE59T/Middleton et al. - 2015 - The National Lung Matrix Trial translating the biology of stratification in advanced non-small-cell lung cance.pdf}
}
@article{Senchenkov2007,
title = {Predictors of {{Survival}} and {{Recurrence}} in the {{Surgical Treatment}} of {{Merkel Cell Carcinoma}} of the {{Extremities}}},
volume = {95},
doi = {10.1002/jso},
number = {3},
journal = {Journal of surgical oncology},
author = {Senchenkov, Alex and Barnes, Sunni and Moran, Steven},
year = {2007},
keywords = {MCC},
pages = {148-155},
file = {/Users/k/Zotero/storage/98W25SF3/Senchenkov, Barnes, Moran - 2007 - Predictors of Survival and Recurrence in the Surgical Treatment of Merkel Cell Carcinoma of the Extre.pdf;/Users/k/Zotero/storage/FUZ8TGK4/Senchenkov, Barnes, Moran - 2007 - Predictors of Survival and Recurrence in the Surgical Treatment of Merkel Cell Carcinoma of the Extre.pdf},
pmid = {17323329}
}
@article{Harrington2014,
title = {Outcomes of {{Merkel Cell Carcinoma Treated}} with {{Radiotherapy}} without {{Radical Surgical Excision}}},
volume = {21},
issn = {1068-9265},
doi = {10.1245/s10434-014-3757-8},
number = {11},
journal = {Annals of Surgical Oncology},
author = {Harrington, Chris and Kwan, Winkle},
year = {2014},
keywords = {MCC},
pages = {3401-3405},
file = {/Users/k/Zotero/storage/AZB3WBZA/Harrington, Kwan - 2014 - Outcomes of Merkel Cell Carcinoma Treated with Radiotherapy without Radical Surgical Excision.pdf;/Users/k/Zotero/storage/YR2ARUKW/Harrington, Kwan - 2014 - Outcomes of Merkel Cell Carcinoma Treated with Radiotherapy without Radical Surgical Excision.pdf}
}
@article{Pape2011,
title = {Radiotherapy Alone for {{Merkel}} Cell Carcinoma: {{A}} Comparative and Retrospective Study of 25 Patients},
volume = {65},
issn = {01909622},
doi = {10.1016/j.jaad.2010.07.043},
abstract = {Background: Merkel cell carcinoma (MCC) is a rare skin cancer. Cumulative data from retrospective series support the notion that benefits are obtained by both wide excision and adjuvant radiation therapy. However, surgery may be difficult to perform with tumors located in the head and neck region and/or in elderly patients with comorbidities incompatible with general anesthesia. Objective: We assessed the benefit of treating MCC exclusively with radiation when conventional treatment (surgery followed by radiotherapy) is not possible. Methods: A total of 25 patients with primary MCC were treated at our institution exclusively with radiotherapy. Because there is no consensus about this specific approach, we compared the recurrence rate of the 25 patients receiving radiotherapy alone with that of 25 patients who received conventional treatment at our institution. Results: The median follow-up periods were 3 years (range: 5 months-11 years) for the group receiving only radiotherapy (group 1) and 9 years (range: 12 months-16 years) for the conventional therapy group (group 2). No local relapses were observed, but two locoregional relapses were observed in group 1, and 4 in group 2. No statistical differences were found in overall and disease-free survival between the two groups of patients. Limitations: The limitation of this study is its retrospective nature. Conclusions: This study confirms the results of our previous research demonstrating that it is possible to treat inoperable MCC exclusively with radiotherapy to obtain an outcome similar to that which is achievable with conventional treatment. ?? 2010 by the American Academy of Dermatology, Inc.},
number = {5},
journal = {Journal of the American Academy of Dermatology},
author = {Pape, Emeline and Rezvoy, Nicolas and Penel, Nicolas and Salleron, Julia and Martinot, Veronique and Guerreschi, Pierre and Dziwniel, Veronique and Darras, Sophie and Mirabel, Xavier and Mortier, Laurent},
year = {2011},
keywords = {MCC,Prognosis,inoperable patient,Merkel cell carcinoma,neuroendocrine tumor,radiation therapy,skin tumor,prognosis},
pages = {983-990},
file = {/Users/k/Zotero/storage/J295KZK8/Pape et al. - 2011 - Radiotherapy alone for Merkel cell carcinoma A comparative and retrospective study of 25 patients.pdf;/Users/k/Zotero/storage/JK4XPFF4/Pape et al. - 2011 - Radiotherapy alone for Merkel cell carcinoma A comparative and retrospective study of 25 patients.pdf},
pmid = {21641081}
}
@article{Allen2005,
title = {Merkel {{Cell Carcinoma}}: {{Prognosis}} and {{Treatment}} of {{Patients From}} a {{Single Institution}}},
volume = {23},
issn = {0732-183X},
doi = {10.1200/JCO.2005.02.329},
number = {10},
journal = {Journal of Clinical Oncology},
author = {Allen, P. J.},
year = {2005},
keywords = {MCC},
pages = {2300-2309},
file = {/Users/k/Zotero/storage/XPACPXX4/Allen - 2005 - Merkel Cell Carcinoma Prognosis and Treatment of Patients From a Single Institution.pdf;/Users/k/Zotero/storage/YBRN9PRV/Allen - 2005 - Merkel Cell Carcinoma Prognosis and Treatment of Patients From a Single Institution.pdf}
}
@article{Lewis2006,
title = {Adjuvant Local Irradiation for {{Merkel}} Cell Carcinoma.},
volume = {142},
issn = {00933619},
doi = {10.1016/S0093-3619(08)70612-9},
abstract = {OBJECTIVES: To determine the effect of adjuvant local irradiation on (1) disease recurrence and (2) survival rates in Merkel cell carcinoma (MCC). DATA SOURCES: An Ovid MEDLINE search (January 1966-May 26, 2004) was performed using the following criteria: group 1, "Merkel cell OR trabecular OR neuroendocrine skin OR APUDoma skin OR primary small cell skin OR primary undifferentiated skin OR endocrine skin OR neuroepithelial" AND group 2, "carcinoma OR tumor OR cancer" with mapping modifiers "-title, -abstract, -keyword, -subject heading." The search yielded 843 citations. STUDY SELECTION: The Ovid set was then searched using the following criteria: "surgery OR radiation OR radiotherapy," which yielded 242 discrete citations. Reports from all 242 citations were reviewed. For the remaining 601 citations, abstracts (when available) were reviewed to assess the level of relevance for potential inclusion; reports from 63 of these citations were reviewed. An additional 28 secondary references were reviewed, for a total of 333 reports. DATA EXTRACTION: The following criteria for inclusion were applied to each potential patient: (1) a histopathologic diagnosis of MCC; (2) a single, primary tumor arising on the skin, for which (3) the primary treatment was surgical excision (local excision, wide excision, or Mohs surgery) with or without the use of adjuvant irradiation (to the tumor bed); (4) following surgery, negative (clear) surgical margins were obtained; (5) during the postoperative follow-up period, disease recurrence, progression, and survival and/or duration of event-free interval was documented with (6) a minimum follow-up of 1 month. A total of 1254 patients were included in the analysis. RESULTS: Statistically significant reductions in local (hazard ratio [HR], 0.27; P $<$ .001) and regional (HR, 0.34; P $<$ .001) recurrence were observed among patients treated with combination therapy compared with surgery alone. Similar rates of distant metastasis were observed between treatment groups (HR, 0.79; P = .31). Overall survival rates were 87\% (1 year) and 49\% (5 years). Cause-specific survival rates were 90\% (1 year) and 62\% (5 year). In general, differences in overall (HR, 0.78; P = .16) and cause-specific (due to MCC: HR, 0.72; P = .14) survival rates between treatment groups did not reach statistical significance. A subgroup analysis that excluded single-patient case reports and studies of only 1 treatment group revealed a significant overall (HR, 0.63; P = .02) and cause-specific (HR, 0.62; P = .04) survival advantage after treatment with combination therapy. CONCLUSIONS: Surgery plus local adjuvant irradiation was associated with significantly lower rates of local and regional recurrence of MCC than surgery alone. Prospective investigation is needed to clarify the presence of a survival benefit from combination therapy.},
number = {6},
journal = {Archives of dermatology},
author = {Lewis, Kevan G and a Weinstock, Martin and Weaver, Amy L and Otley, Clark C},
year = {2006},
keywords = {MCC},
pages = {693-700},
file = {/Users/k/Zotero/storage/9DT7I4FQ/Lewis et al. - 2006 - Adjuvant local irradiation for Merkel cell carcinoma.pdf;/Users/k/Zotero/storage/BXBRJU9E/Lewis et al. - 2006 - Adjuvant local irradiation for Merkel cell carcinoma.pdf},
pmid = {16785371}
}
@article{Paoletti2015,
title = {Statistical Controversies in Clinical Research: Requiem for the 3 + 3 Design for Phase {{I}} Trials},
volume = {26},
issn = {0923-7534},
doi = {10.1093/annonc/mdv266},
number = {9},
journal = {Annals of Oncology},
author = {Paoletti, X. and Ezzalfani, M. and Le Tourneau, C.},
year = {2015},
keywords = {Continual reassessment method,Dose finding,efficiency,targeted agents,continual reassessment method,dose finding,Anti3+3},
pages = {1808-1812},
file = {/Users/k/Zotero/storage/FQNN874B/Paoletti, Ezzalfani, Le Tourneau - 2015 - Statistical controversies in clinical research requiem for the 3 3 design for phase I trials.pdf}
}
@article{Taylor2009,
title = {The Use of Surrogate Outcomes in Model-Based Cost-Effectiveness Analyses: A Survey of {{UK Health Technology Assessment}} Reports},
volume = {13},
issn = {1366-5278},
doi = {10.3310/hta13080},
number = {8},
journal = {Health Technology Assessment},
author = {Taylor, R and Elston, J},
year = {2009},
keywords = {SurrogateOutcomes,COST-EFFECTIVENESS-MODEL,FINAL-OUTCOME,HEALTH-TECHNOLOGY-ASSESSMENT,SURROGATE-OUTCOME},
file = {/Users/k/Zotero/storage/KHZZWERW/Taylor, Elston - 2009 - The use of surrogate outcomes in model-based cost-effectiveness analyses a survey of UK Health Technology Assess.pdf;/Users/k/Zotero/storage/SLTTTETY/Taylor, Elston - 2009 - The use of surrogate outcomes in model-based cost-effectiveness analyses a survey of UK Health Technology Assess.pdf}
}
@article{Ciani2013,
title = {Comparison of Treatment Effect Sizes Associated with Surrogate and Final Patient Relevant Outcomes in Randomised Controlled Trials: Meta-Epidemiological Study},
volume = {346},
issn = {1756-1833},
doi = {10.1136/bmj.f457},
number = {jan29 1},
journal = {Bmj},
author = {Ciani, O. and Buyse, M. and Garside, R. and Pavey, T. and Stein, K. and Sterne, J. a. C. and Taylor, R. S.},
year = {2013},
keywords = {SurrogateOutcomes},
pages = {f457-f457},
file = {/Users/k/Zotero/storage/F54T93TI/Ciani et al. - 2013 - Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised c.pdf;/Users/k/Zotero/storage/Z42ERFVW/Ciani et al. - 2013 - Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised c.pdf}
}
@article{Garrido2009,
title = {Surrogate Outcomes in Health Technology Assessment: {{An}} International Comparison},
volume = {25},
issn = {0266-4623},
doi = {10.1017/S0266462309990213},
number = {03},
journal = {International Journal of Technology Assessment in Health Care},
author = {Garrido, Marcial Velasco and Mangiapane, Sandra},
year = {2009},
keywords = {Biological Markers,Intermedia,intermediate outcomes,outcome,Surrogate outcomes,biological markers,surrogate outcomes,Surrogate outcomes; Biological Markers; Intermedia},
pages = {315},
file = {/Users/k/Zotero/storage/MB2FMBIM/Garrido, Mangiapane - 2009 - Surrogate outcomes in health technology assessment An international comparison.pdf;/Users/k/Zotero/storage/Z753AEAA/Garrido, Mangiapane - 2009 - Surrogate outcomes in health technology assessment An international comparison.pdf}
}
@article{Topalian2012,
title = {Safety, {{Activity}}, and {{Immune Correlates}} of {{Anti}}\textendash{{PD}}-1 {{Antibody}} in {{Cancer}}},
journal = {The New England journal of medicineNew},
author = {Suzanne L. Topalian, M.D. and F. Stephen Hodi, M.D. and Julie R. Brahmer, M.D. and Scott N. Gettinger, M.D. and David C. Smith, M.D. and David F. McDermott, M.D. and John D. Powderly, M.D. and Richard D. Carvajal, M.D. and Jeffrey A. Sosman, M.D. and Michael B. Atkins, M.D. and Philip D. Leming, M.D. and David R. Spigel, M.D. and Scott J. Antonia, M.D., Ph.D., Leora Horn, M.D. and Charles G. Drake, M.D., Ph.D., Drew M. Pardoll, M.D., Ph.D., Lieping Chen, M.D., Ph.D., William H. Sharfman, M.D., Robert A. Anders, M.D., Ph.D., Janis M. Taube, M.D. and Tracee L. McMiller, M.S. and Haiying Xu, B.A. and Alan J. Korman, Ph.D. and {Maria Jure-Kunkel}, Ph.D. and Shruti Agrawal, Ph.D. and Daniel McDonald, M.B.A. and Georgia D. Kollia, Ph.D. and Ashok Gupta, M.D., Ph.D. and Jon M. Wigginton, M.D. and Mario Sznol, M.D.},
year = {2012},
keywords = {NSCLC,PD1,Nivolumab},
pages = {2443-2454},
file = {/Users/k/Zotero/storage/A8PNNH4D/Svensson et al. - 2011 - Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer.pdf;/Users/k/Zotero/storage/US5XT8SK/Suzanne L. Topalian et al. - 2012 - Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer.pdf}
}
@article{Dimairo2015,
title = {Missing Steps in a Staircase: A Qualitative Study of the Perspectives of Key Stakeholders on the Use of Adaptive Designs in Confirmatory Trials},
volume = {16},
issn = {1745-6215},
doi = {10.1186/s13063-015-0958-9},
number = {1},
journal = {Trials},
author = {Dimairo, Munyaradzi and Boote, Jonathan and a. Julious, Steven and Nicholl, Jonathan P. and Todd, Susan},
year = {2015},
keywords = {clinical trials,early stopping,uk,ac,correspondence,Adaptive designs,confirmatory trials,dimairo,Flexible designs,funded trials,interim analyses,m,phase 3,publicly,Qualitative inte,qualitative interviews,sheffield,adaptive designs,Adaptive designs;Flexible designs;Qualitative inte,flexible designs},
pages = {430},
file = {/Users/k/Zotero/storage/BLDQGPKZ/Dimairo et al. - 2015 - Missing steps in a staircase a qualitative study of the perspectives of key stakeholders on the use of adaptive.pdf;/Users/k/Zotero/storage/DTDB2VG3/Dimairo et al. - 2015 - Missing steps in a staircase a qualitative study of the perspectives of key stakeholders on the use of adaptive.pdf}
}
@book{Spiegelhalter2004,
title = {Bayesian {{Approaches}} to {{Clinical Trials}} and {{Helath}}-{{Care Evaluation}}},
isbn = {0-471-49975-7},
author = {Spiegelhalter, David J. and Abrams, Keith R. and Myles, Jonathan P.},
year = {2004},
keywords = {bayesian,Books,Bayesian},
file = {/Users/k/Zotero/storage/8ZG99BAX/Spiegelhalter, Abrams, Myles - 2004 - Bayesian Approaches to Clinical Trials and Helath-Care Evaluation.pdf;/Users/k/Zotero/storage/PLTWL29P/Spiegelhalter, Abrams, Myles - 2004 - Bayesian Approaches to Clinical Trials and Helath-Care Evaluation.pdf}
}
@article{Lachin1986,
title = {Evaluation of {{Sample Size}} and {{Power}} for {{Analyses}} of {{Survival}} with {{Allowance}} for {{Nonuniform Patient Entry}}, {{Losses}} to {{Follow}}-up, {{Noncompliance}}, and {{Stratification}}.Pdf},
volume = {42},
number = {3},
journal = {Biometrics},
author = {Lachin, John M and Foulkes, Mary A},
year = {1986},
keywords = {Phase III},
pages = {507-519},
file = {/Users/k/Zotero/storage/5UVJQX9P/Lachin, Foulkes - 1986 - Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losse.pdf;/Users/k/Zotero/storage/KRVFXQP6/Lachin, Foulkes - 1986 - Evaluation of Sample Size and Power for Analyses of Survival with Allowance for Nonuniform Patient Entry, Losse.pdf}
}
@article{Thatcher2005,
title = {Gefitinib plus Best Supportive Care in Previously Treated Patients with Refractory Advanced Non-Small-Cell Lung Cancer: {{Results}} from a Randomised, Placebo-Controlled, Multicentre Study ({{Iressa Survival Evaluation}} in {{Lung Cancer}})},
volume = {366},
issn = {01406736},
doi = {10.1016/S0140-6736(05)67625-8},
abstract = {Background: This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. Methods: 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. Findings: 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7$\cdot$2 months, median survival did not differ significantly between the groups in the overall population (5$\cdot$6 months for gefitinib and 5$\cdot$1 months for placebo; hazard ratio 0$\cdot$89 [95\% CI 0$\cdot$77-1$\cdot$02], p=0$\cdot$087) or among the 812 patients with adenocarcinoma (6$\cdot$3 months vs 5$\cdot$4 months; 0$\cdot$84 [0$\cdot$68-1$\cdot$03], p=0$\cdot$089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0$\cdot$67 [0$\cdot$49-0$\cdot$92], p=0$\cdot$012; median survival 8$\cdot$9 vs 6$\cdot$1 months) and patients of Asian origin (n=342; 0$\cdot$66 [0$\cdot$48-0$\cdot$91], p=0$\cdot$01; median survival 9$\cdot$5 vs 5$\cdot$5 months). Gefitinib was well tolerated, as in previous studies. Interpretation: Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.},
number = {9496},
journal = {Lancet},
author = {Thatcher, Nick and Chang, Alex and Parikh, Purvish and Pereira, Jos\'e Rodrigues and Ciuleanu, Tudor and Von Pawel, Joachim and Thongprasert, Sumitra and Tan, Eng Huat and Pemberton, Kristine and Archer, Venice and Carroll, Kevin},
year = {2005},
pages = {1527-1537},
file = {/Users/k/Zotero/storage/I4GMPV5L/Thatcher et al. - 2005 - Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung.pdf;/Users/k/Zotero/storage/TH2G4XZI/Thatcher et al. - 2005 - Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung.pdf},
pmid = {16257339}
}
@article{Salter2015a,
title = {B i o s t a t i s t i c s {{D}} e p a r t m e n t {{T}} e c h n i c a l {{R}} e p o r t {{B S T}} 2 0 1 5 - 0 0 1 {{T}} w o - {{G}} r o u p {{T}} i m e - {{T}} o - {{E}} v e n t {{C}} o n t i n u a l {{R}} e a s s e s s m e n t {{M}} e t h o d {{U}} s i n g {{L}} i k e l i h o o d {{E}} s t i m a t i o n {{A}} m b e R},
author = {Salter, Amber and O'Quigley, J and Cutter, G and Aban, I},
keywords = {DoseFinding,CRM},
file = {/Users/k/Zotero/storage/PZS36KIZ/Salter et al. - Unknown - B i o s t a t i s t i c s D e p a r t m e n t T e c h n i c a l R e p o r t B S T 2 0 1 5 - 0 0 1 T w o - G r.pdf;/Users/k/Zotero/storage/SRRIF3RR/Salter et al. - Unknown - B i o s t a t i s t i c s D e p a r t m e n t T e c h n i c a l R e p o r t B S T 2 0 1 5 - 0 0 1 T w o - G r.pdf}
}
@article{OQuigley1999,
title = {Two-Sample Continual Reassessment Method.},
volume = {9},
issn = {1054-3406},
doi = {10.1081/BIP-100100998},
abstract = {We discuss an extension of the continual reassessment method (CRM) for use in phase I dose-finding studies. The extension enables the method to be applied to two groups of patients to determine the appropriate dose levels for each group. The method takes the specification of a simple relationship between the dose-toxicity curves for the two groups and runs the CRM on the bivariate model using maximum likelihood. We prove consistency of the method under fairly weak conditions and provide several simulations to give an idea how the method works in practice. We also undertake an evaluation of its performance by considering three possible situations: The first is the two-sample CRM, which directly uses a working model for the relationship between the two groups, carrying out a single trial using this method; the second situation carries out single trials for each of the two groups separately using the original (one-sample) CRM. The third situation is the case where such heterogeneity is ignored and the two groups are pooled into a single group, again using the original (one-sample) CRM. Simulations are carried out under a large class of model misspecifications, both of the dose-toxicity relationships and of the functional form linking the groups, and are backed up by asymptotic results. Our conclusions match intuition: The first scheme gives the most favorable results when the two groups are different but share some features. When the groups are very different, the second scheme performs similarly to the first for finite sample sizes while having some advantages in terms of asymptotic efficiency. The third, as expected, gives the best results in the absence of patient heterogeneity. The two-sample method appears particularly advantageous when there may not be enough subjects in one of the subgroups for it to be feasible to carry out two trials.},
number = {1},
journal = {Journal of biopharmaceutical statistics},
author = {O'Quigley, J and Shen, L Z and Gamst, A},
year = {1999},
keywords = {DoseFinding,CRM},
pages = {17-44},
file = {/Users/k/Zotero/storage/8KV5I66V/O'Quigley, Shen, Gamst - 1999 - Two-sample continual reassessment method.pdf;/Users/k/Zotero/storage/Z5WZ5W2V/O'Quigley, Shen, Gamst - 1999 - Two-sample continual reassessment method.pdf},
pmid = {10091908}
}
@article{Murtaugh1990,
title = {Bivariate {{Binary Models}} of {{Efficacy}} and {{Toxicity}} in {{Dose}}-{{Ranging Trials}}},
volume = {19},
number = {6},
journal = {Communications in Statistics-Theory and Methods},
author = {Murtaugh, Paul A. and Fisher, L},
year = {1990},
keywords = {EfficacyToxicity},
pages = {2003-2020},
file = {/Users/k/Zotero/storage/SIJKMC7Q/Murtaugh, Fisher - 1990 - cis-1990.pdf.pdf;/Users/k/Zotero/storage/YR3T2NEM/Murtaugh, Fisher - 1990 - Bivariate Binary Models of Efficacy and Toxicity in Dose-Ranging Trials.pdf}
}
@article{Salter2013,
title = {Evaluating {{Approaches}} in {{Dose Finding}} for {{Two Groups Using}} the {{Time}}-to-{{Event Continual Reassessment Method}}},
author = {Salter, Amber and Al, Et},
year = {2013},
keywords = {CRM,MyReviews},
file = {/Users/k/Zotero/storage/8HQTA33V/Salter, Al - 2013 - Evaluating Approaches in Dose Finding for Two Groups Using the Time-to-Event Continual Reassessment Method.pdf;/Users/k/Zotero/storage/KHW678CJ/Salter, Al - 2013 - Evaluating Approaches in Dose Finding for Two Groups Using the Time-to-Event Continual Reassessment Method.pdf}
}
@article{Ivanova2009,
title = {An Adaptive Design for Identifying the Dose with the Best Efficacy/Tolerability Profile with Application to a Crossover Dose-Finding Study},
volume = {28},
number = {15},
journal = {Statistics in medicine},
author = {Ivanova, Anastasia (University of North Carolina) and Liu, Ken and Snyder, Ellen and Snavely, Duane},
year = {2009},
keywords = {Dose finding,proof-of-concept trial,utility function,dose finding},
pages = {1999-2011},
file = {/Users/k/Zotero/storage/ST8NVI2W/Ivanova et al. - 2009 - An adaptive design for identifying the dose with the best efficacytolerability profile with application to a cro.pdf;/Users/k/Zotero/storage/WVITEMG4/Ivanova et al. - 2009 - An adaptive design for identifying the dose with the best efficacytolerability profile with application to a cro.pdf},
pmid = {19455509}
}
@article{Wang2010,
title = {Adaptive {{Bayesian}} Design for Phase {{I}} Dose-Finding Trials Using a Joint Model of Response and Toxicity.},
volume = {20},
issn = {1054-3406},
doi = {10.1080/10543400903280613},
abstract = {We present a new adaptive Bayesian method for dose-finding in phase I clinical trials based on both response and toxicity. Although clinical responses are usually rare in phase I cancer trials, molecularly targeted therapy may make clinical responses more likely. In addition, biological responses may be common. Thus responses may be frequent enough to help decide how aggressive a phase I escalation should be. The model assumes that response and toxicity events happen depending on respective dose thresholds for the individual, assuming that the thresholds jointly follow a bivariate log-normal distribution or a mixture. The design utilizes prior information about the population threshold distribution as well as accumulated data. The next dose is assigned to maximize a patient-oriented expected utility integrated over the current posterior distribution. The design is evaluated through simulation with population parameters equaling estimates from early Gleevec trials. This exercise provides evidence for the value of the use of the proposed design for future clinical trials.},
number = {1},
journal = {Journal of biopharmaceutical statistics},
author = {Wang, Meihua and Day, Roger},
year = {2010},
keywords = {DoseFinding,EfficacyToxicity},
pages = {125-144},
file = {/Users/k/Zotero/storage/GZZC5VSB/Wang, Day - 2010 - Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.pdf;/Users/k/Zotero/storage/W7K6KKFA/Wang, Day - 2010 - Adaptive Bayesian design for phase I dose-finding trials using a joint model of response and toxicity.pdf},
pmid = {20077253}
}
@article{Ivanova2003,
title = {A {{New Dose}}-{{Finding Design}} for {{Bivariate Outcomes}}},
volume = {59},
issn = {0006341X},
doi = {10.1111/j.0006-341X.2003.00115.x},
abstract = {For some drugs, toxicity events lead to early termination of treatment before a therapeutic response is observed. That is, there are three possible outcomes: toxicity (therapeutic response unknown), therapeutic response without toxicity, and no response with no toxicity. The optimal dose is the dose that maximizes the probability of the joint event, response, and no toxicity. The optimal safe dose is the dose, from among the doses with toxicity rate less than the maximum tolerable level, that maximizes the probability of response and no toxicity. We present a new sequential design to maximize the number of subjects assigned in the neighborhood of the optimal safe dose in a dose-finding trial with two outcomes.},
number = {4},
journal = {Biometrics},
author = {Ivanova, Anastasia},
year = {2003},
keywords = {phase i trial,dose-finding studies,Optimal dose,Random walk,Up-and-down design,Dose-finding studies,Phase I trial},
pages = {1001-1007},
file = {/Users/k/Zotero/storage/3KFIEEZR/Ivanova - 2003 - A New Dose-Finding Design for Bivariate Outcomes.pdf;/Users/k/Zotero/storage/EY7XG8VA/Ivanova - 2003 - A New Dose-Finding Design for Bivariate Outcomes.pdf},
pmid = {14969479}
}
@article{Zhang2006,
title = {An Adaptive Dose-Finding Design Incorporating Both Toxicity and Efficacy},
volume = {25},
issn = {02776715},
doi = {10.1002/sim.2325},
abstract = {Novel therapies are challenging the standards of drug development. Agents with specific biologic targets and limited toxicity require novel designs to determine doses to be taken forward into larger studies. In this paper, we describe an approach that incorporates both toxicity and efficacy data into the estimation of the biologically optimal dose of an agent in a phase I trial. The approach is based on the flexible continuation-ratio model, and uses straightforward optimal dose selection criteria. Dose selection is based on all patients treated up until that time point, using a continual reassessment method approach. Dose-outcome curves considered include monotonically increasing, monotonically decreasing, and unimodal curves. Our simulation studies demonstrate that the proposed design, which we call TriCRM, has favourable operating characteristics.},
number = {14},
journal = {Statistics in Medicine},
author = {Zhang, Wei and Sargent, Daniel J. and Mandrekar, Sumithra},
year = {2006},
keywords = {DoseFinding,Continual reassessment method,CRM,EfficacyToxicity,Bayesian method,Continuation-ratio model,Phase I trail,Proportional odds model,Trinomial},
pages = {2365-2383},
file = {/Users/k/Zotero/storage/2EQQDAAC/Zhang, Sargent, Mandrekar - 2006 - An adaptive dose-finding design incorporating both toxicity and efficacy.pdf;/Users/k/Zotero/storage/XUIDSP2T/Zhang, Sargent, Mandrekar - 2006 - An adaptive dose-finding design incorporating both toxicity and efficacy.pdf},
pmid = {16220478}
}
@article{Brutti2011,
title = {An Extension of the Single Threshold Design for Monitoring Efficacy and Safety in Phase {{II}} Clinical Trials},
volume = {30},
issn = {02776715},
doi = {10.1002/sim.4229},
abstract = {Tan and Machin (biStat. Med. 2002; 21:1991-2012) introduce a Bayesian two-stage design for phase II clinical trials where the binary endpoint of interest is treatment efficacy. In this paper we propose an extension of their design to incorporate safety considerations. At each stage we define the treatment successful and deserving of further study if the total number of adverse events is sufficiently small and the number of responders who simultaneously do not experience any toxicity is sufficiently large. Therefore, our criterion is based on the joint posterior probability that the true overall toxicity rate and the true efficacy-and-safety rate are, respectively, smaller and larger than conveniently pre-specified target values. The optimal two-stage sample sizes are determined specifying a minimum threshold for the above-mentioned posterior probability, computed under the assumption that favorable outcomes have occurred. Besides describing the proposed design, we suggest how to construct informative prior scenarios and we also apply the reference algorithm to derive a non-informative prior distribution. Finally, some numerical results are provided and a real data application is illustrated.},
number = {14},
journal = {Statistics in Medicine},
author = {Brutti, P. and Gubbiotti, S. and Sambucini, V.},
year = {2011},
keywords = {EfficacyToxicityPhaseII,Two-stage design,bayesian design,Binary outcomes,Multiple endpoints,Phase II clinical trials,Bayesian design},
pages = {1648-1664},
file = {/Users/k/Zotero/storage/E8CEF7RM/Brutti, Gubbiotti, Sambucini - 2011 - An extension of the single threshold design for monitoring efficacy and safety in phase II clinica.pdf;/Users/k/Zotero/storage/ICC7ZPFK/Brutti, Gubbiotti, Sambucini - 2011 - An extension of the single threshold design for monitoring efficacy and safety in phase II clinica.pdf},
pmid = {21520453}
}
@article{Mandrekar2010,
title = {Model-Based Phase {{I}} Designs Incorporating Toxicity and Efficacy for Single and Dual Agent Drug Combinations: {{Methods}} and Challenges},
volume = {29},
issn = {02776715},
doi = {10.1002/sim.3706},
abstract = {Novel therapies are challenging the standards of drug development. Agents with specific biologic targets, unknown dose-efficacy curves, and limited toxicity mandate novel designs to identify biologically optimal doses. We review two model-based designs that utilize either a proportional odds model or a continuation ratio model to identify an optimal dose of a single or two-agent combination in a Phase I setting utilizing both toxicity and efficacy data. A continual reassessment method with straightforward dose selection criterion using accumulated data from all patients treated until that time point is employed while allowing for separate toxicity and efficacy curves for each drug in a two-drug setting. The simulation studies demonstrate considerable promise, at least theoretically, in the ability of such model-based designs to identify the optimal dose. Despite such favorable operating characteristics, there are several pragmatic challenges that hinder the routine implementation of such model-based designs in practice. We review and offer practical solutions to potentially overcome some of these challenges. The acceptance and integration of these designs in practice may be quicker and easier if they are developed in concert with a clinical paradigm.},
number = {10},
journal = {Statistics in Medicine},
author = {Mandrekar, Sumithra J. and Qin, Rui and Sargent, Daniel J.},
year = {2010},
keywords = {DoseFinding,Continual reassessment method,efficacy,toxicity,EfficacyToxicity,dose-finding,Model-based designs,Trinary outcome,Dose-finding,Efficacy,Toxicity,model-based designs},
pages = {1077-1083},
file = {/Users/k/Zotero/storage/333S86ED/Mandrekar, Qin, Sargent - 2010 - Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinat.pdf;/Users/k/Zotero/storage/6ABSI34N/Mandrekar, Qin, Sargent - 2010 - Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinat.pdf},
pmid = {20419760}
}
@article{Jennison1993,
title = {Group Sequential Tests for Bivariate Response: Interim Analyses of Clinical Trials with Both Efficacy and Safety Endpoints.},
volume = {49},
issn = {0006-341X},
abstract = {We describe group sequential tests for a bivariate response. The tests are defined in terms of the two response components jointly, rather than through a single summary statistic. Such methods are appropriate when the two responses concern different aspects of a treatment; for example, one might wish to show that a new treatment is both as effective and as safe as the current standard. We present a formulation of the bivariate testing problem, introduce group sequential tests that satisfy Type I error conditions, and show how to find the sample size guaranteeing a specified power. We describe how properties of group sequential tests for bivariate normal observations can be computed by numerical integration.},
number = {3},
journal = {Biometrics},
author = {Jennison, C and Turnbull, B W},
year = {1993},
keywords = {EfficacyToxicityPhaseII,bivariate},
pages = {741-752},
file = {/Users/k/Zotero/storage/8IK95KGI/Jennison, Turnbull - 1993 - Group sequential tests for bivariate response interim analyses of clinical trials with both efficacy and saf.pdf;/Users/k/Zotero/storage/VESPBQWF/Jennison, Turnbull - 1993 - Group sequential tests for bivariate response interim analyses of clinical trials with both efficacy and saf.pdf},
pmid = {8241370}
}
@article{Conaway1995,
title = {Bivariate Sequential Designs for Phase {{II}} Trials.},
volume = {51},
issn = {0006341X},
doi = {10.2307/2532952},
abstract = {In this paper we propose methods for designing group sequential phase II trials with two dependent binary endpoints. The emphasis is on the derivation of stopping rules for phase II trials which require the enrollment of a small number of patients. The methods are based on enumerating the exact distribution for the binary endpoints. We illustrate the methods with a recent study which required the use of group sequential design to monitor antitumor activity and toxicity.},
number = {2},
journal = {Biometrics},
author = {Conaway, M R and Petroni, G R},
year = {1995},
keywords = {EfficacyToxicityPhaseII},
pages = {656-664},
file = {/Users/k/Zotero/storage/IU5X6Z2W/Conaway, Petroni - 1995 - Bivariate sequential designs for phase II trials.pdf;/Users/k/Zotero/storage/LWJ5HFFN/Conaway, Petroni - 1995 - Bivariate sequential designs for phase II trials.pdf},
pmid = {7662852}
}
@article{Conaway1996,
title = {Designs for Phase {{II}} Trials Allowing for a Trade-off between Response and Toxicity.},
volume = {52},
issn = {0006-341X},
doi = {10.2307/2532851},
abstract = {In this paper we propose methods for designing phase II trials that allow for a trade-off between treatment safety and antitumor activity, where safety and antitumor activity are measured as binary endpoints. The designs can be carried out either in a single stage or can be conducted in two stages, with an interim analysis to assess whether the treatment appears sufficiently safe and effective to warrant continuing. The emphasis is on the derivation of stopping rules for phase II trials that require the enrollment of a small number of patients and are based on enumerating the exact distribution of the proposed test statistic. We illustrate the methods with a recent study that required the use of a group sequential design to monitor antitumor activity and toxicity.},
number = {4},
journal = {Biometrics},
author = {Conaway, M R and Petroni, G R},
year = {1996},
keywords = {EfficacyToxicityPhaseII},
pages = {1375-1386},
file = {/Users/k/Zotero/storage/7UH4SQ7Q/Conaway, Petroni - 1996 - Designs for phase II trials allowing for a trade-off between response and toxicity.pdf;/Users/k/Zotero/storage/M9VEI6BH/Conaway, Petroni - 1996 - Designs for phase II trials allowing for a trade-off between response and toxicity.pdf},
pmid = {8962459}
}
@article{Jin2007,
title = {Alternative Designs of Phase {{II}} Trials Considering Response and Toxicity},
volume = {28},
issn = {15517144},
doi = {10.1016/j.cct.2007.03.003},
abstract = {Phase II clinical trials in oncology are used to initially evaluate the therapeutic efficacy of a new treatment regimen. Simon's two-stage design is commonly used for such trials. However, he only focused on the "response rate", the proportion of patients experiencing tumor regression. In clinical practice, it is preferred of a sequential design to monitor antitumor activity as well as toxicity. Conaway and Petroni proposed a method for designing phase II trials on the basis of both treatment efficacy and safety, which imply an equal weighing of response and toxicity. In this paper, we developed an alternative test to cope with the trade-off between safety and efficacy. The main idea is to control for the marginal type I errors of response rate and toxicity rate separately. We provide guides on searching the stopping and rejecting regions and determination of sample size. The proposed method has advantage over other designs, including those of Conaway and Petroni's and Bryant and Day's, that it can definitely control one type I error of the interests such as treatment antitumor activity or safety and is robust against the real association parameter. Furthermore, it is conceptive intuitive, very simple to implement, and also feasible for the requirement of small sample size in a phase II trial. ?? 2007 Elsevier Inc. All rights reserved.},
number = {4},
journal = {Contemporary Clinical Trials},
author = {Jin, Hua},
year = {2007},
keywords = {EfficacyToxicityPhaseII,Phase II clinical trial,Robust,Two-stage design,Type I error},
pages = {525-531},
file = {/Users/k/Zotero/storage/VHKHVJWH/Jin - 2007 - Alternative designs of phase II trials considering response and toxicity.pdf;/Users/k/Zotero/storage/XTEREM6W/Jin - 2007 - Alternative designs of phase II trials considering response and toxicity.pdf},
pmid = {17428744}
}
@article{Bouckaert2001,
title = {Sure Outcomes of Random Events: {{A}} Model for Clinical Trials},
volume = {20},
issn = {02776715},
doi = {10.1002/sim.659},
abstract = {We consider the outcomes of a clinical trial as determined by one, or several, possibly hidden causes. This paper proposes a statistical model that allows such a distinction of causes not only for the main, or therapeutic, effects but also for the side, or toxic, effects. More specifically, we focus on trials where the effects are naturally dichotomized, that is, where the health of a patient has improved or not, and where a specific adverse effect has occurred or not. A case study provides an example of the way this model can help to solve some problems of suspected drug toxicity. Finally, the model is shown to be a part of a hierarchy of models and the way to select a best model is investigated.},
number = {4},
journal = {Statistics in Medicine},
author = {Bouckaert, A. and Mouchart, M.},
year = {2001},
keywords = {EfficacyToxicityPhaseII},
pages = {521-543},
file = {/Users/k/Zotero/storage/HAB7DKVR/Bouckaert, Mouchart - 2001 - Sure outcomes of random events A model for clinical trials.pdf;/Users/k/Zotero/storage/VML8ZVWV/Bouckaert, Mouchart - 2001 - Sure outcomes of random events A model for clinical trials.pdf},
pmid = {11223899}
}
@article{Cook1994,
title = {Guidelines for Monitoring Efficacy and Toxicity Responses in Clinical Trials.},
volume = {50},
issn = {0006-341X},
doi = {10.2307/2533451},
abstract = {There is currently a need for clinical trial methodology that allows formal consideration of toxicity responses. Since a complete evaluation of an experimental therapy addresses both relative efficacy and relative toxicity, general methods for handling bivariate response data are of interest. A procedure for sequentially analysing both efficacy and toxicity data is presented. The procedure is designed to allow early termination due to efficacy results, toxicity results, or both. The method is based on modified marginal sequential analyses, accounting for bivariate correlated responses and multiple analyses over time. The theory is presented in the context of normally distributed responses. Extensions to bivariate failure time data are indicated and an example from a kidney transplant study demonstrates the procedure.},
number = {4},
journal = {Biometrics},
author = {Cook, R J and Farewell, V T},
year = {1994},
keywords = {EfficacyToxicityPhaseII},
pages = {1146-1152},
file = {/Users/k/Zotero/storage/6J2EPSNP/Cook, Farewell - 1994 - Guidelines for monitoring efficacy and toxicity responses in clinical trials.pdf;/Users/k/Zotero/storage/DDN5EX8K/Cook, Farewell - 1994 - Guidelines for monitoring efficacy and toxicity responses in clinical trials.pdf},
pmid = {7786995}
}
@article{Ghebretinsae2012,
title = {Joint Modeling of Hierarchically Clustered and Overdispersed Non-Gaussian Continuous Outcomes for Comet Assay Data},
volume = {11},
issn = {15391604},
doi = {10.1002/pst.1533},
abstract = {Multivariate longitudinal or clustered data are commonly encountered in clinical trials and toxicological studies. Typically, there is no single standard endpoint to assess the toxicity or efficacy of the compound of interest, but co-primary endpoints are available to assess the toxic effects or the working of the compound. Modeling the responses jointly is thus appealing to draw overall inferences using all responses and to capture the association among the responses. Non-Gaussian outcomes are often modeled univariately using exponential family models. To accommodate both the overdispersion and hierarchical structure in the data, Molenberghs et al. A family of generalized linear models for repeated measures with normal and conjugate random effects. Statistical Science 2010; 25:325-347 proposed using two separate sets of random effects. This papers considers a model for multivariate data with hierarchically clustered and overdispersed non-Gaussian data. Gamma random effect for the over-dispersion and normal random effects for the clustering in the data are being used. The two outcomes are jointly analyzed by assuming that the normal random effects for both endpoints are correlated. The association structure between the response is analytically derived. The fit of the joint model to data from a so-called comet assay are compared with the univariate analysis of the two outcomes. Copyright \textcopyright{} 2012 John Wiley \& Sons, Ltd.},
number = {6},
journal = {Pharmaceutical Statistics},
author = {Ghebretinsae, Aklilu Habteab and Faes, Christel and Molenberghs, Geert and Geys, Helena and Van Der Leede, Bas Jan},
year = {2012},
keywords = {EfficacyToxicityPhaseII,comet assay,gamma random effect,hierarchical model,joint model,normal random effect},
pages = {449-455},
file = {/Users/k/Zotero/storage/FQ3SB2EB/Ghebretinsae et al. - 2012 - Joint modeling of hierarchically clustered and overdispersed non-gaussian continuous outcomes for comet ass.pdf;/Users/k/Zotero/storage/WIHH7T9P/Ghebretinsae et al. - 2012 - Joint modeling of hierarchically clustered and overdispersed non-gaussian continuous outcomes for comet ass.pdf},
pmid = {22997130}
}
@article{Cheung2000,
title = {Sequential Designs for Phase {{I}} Clinical Trials with Late-Onset Toxicities.},
volume = {56},
issn = {0006-341X},
abstract = {Traditional designs for phase I clinical trials require each patient (or small group of patients) to be completely followed before the next patient or group is assigned. In situations such as when evaluating late-onset effects of radiation or toxicities from chemopreventive agents, this may result in trials of impractically long duration. We propose a new method, called the time-to-event continual reassessment method (TITE-CRM), that allows patients to be entered in a staggered fashion. It is an extension of the continual reassessment method (CRM; O'Quigley, Pepe, and Fisher, 1990, Biometrics 46, 33-48). We also note that this time-to-toxicity approach can be applied to extend other designs for studies of short-term toxicities. We prove that the recommended dose given by the TITE-CRM converges to the correct level under certain conditions. A simulation study shows our method's accuracy and safety are comparable with CRM's while the former takes a much shorter trial duration: a trial that would take up to 12 years to complete by the CRM could be reduced to 2-4 years by our method.},
number = {4},
journal = {Biometrics},
author = {Cheung, Y K and Chappell, R},
year = {2000},
keywords = {DoseFinding,Continual reassessment method,CRM,TITE-CRM,phase i trial,dose limiting,late-onset toxicities,likelihood-based design,time-to-event,continual reassessment method},
pages = {1177-1182},
file = {/Users/k/Zotero/storage/5CKU7WF4/Cheung, Chappell - 2000 - Sequential designs for phase I clinical trials with late-onset toxicities.pdf;/Users/k/Zotero/storage/7HTGQ6VU/Cheung, Chappell - 2000 - Sequential designs for phase I clinical trials with late-onset toxicities.pdf},
pmid = {11129476}
}
@article{Deng2014,
title = {Bayesian Modeling and Prediction of Accrual in Multi-Regional Clinical Trials},
issn = {0962-2802},
doi = {10.1177/0962280214557581},
journal = {Statistical Methods in Medical Research},
author = {Deng, Y. and Zhang, X. and Long, Q.},
year = {2014},
keywords = {clinical trials,Accrual,bayesian modeling,multi-regional trials,nonhomogeneous poisson process,patient accrual},
file = {/Users/k/Zotero/storage/YD8BYZR6/Deng, Zhang, Long - 2014 - Bayesian modeling and prediction of accrual in multi-regional clinical trials.pdf}
}
@techreport{Wason,
title = {Supplementary Material for `` {{Using}} Continuous Data on Tumour Measurements to Improve Inference in Phase {{II}} Cancer Studies ''},
author = {Wason, James and Seaman, Shaun R.},
keywords = {Anti-dichotomisation},
pages = {1-9},
file = {/Users/k/Zotero/storage/N978A7WS/Wason, Seaman - Unknown - Supplementary material for “ Using continuous data on tumour measurements to improve inference in phase II.pdf}
}
@article{Brown2001,
title = {Interval {{Estimation}} for a {{Binomial Proportion}}},
volume = {16},
issn = {0883-4237},
doi = {10.1214/ss/1009213286},
abstract = {We revisit the problem of interval estimation of a binomial proportion. The erratic behavior of the coverage probability of the stan- dard Wald confidence interval has previously been remarked on in the literature (Blyth and Still, Agresti and Coull, Santner and others). We begin by showing that the chaotic coverage properties of the Wald inter- val are far more persistent than is appreciated. Furthermore, common textbook prescriptions regarding its safety are misleading and defective in several respects and cannot be trusted. This leads us to consideration of alternative intervals. A number of natural alternatives are presented, each with its motivation and con- text. Each interval is examined for its coverage probability and its length. Based on this analysis, we recommend the Wilson interval or the equal- tailed Jeffreys prior interval for small n and the interval suggested in Agresti and Coull for larger n. We also provide an additional frequentist justification for use of the Jeffreys interval},
number = {2},
journal = {Statistical Science},
author = {Brown, Lawrence D. and Cai, T. Tony and DasGupta, Anirban},
year = {2001},
keywords = {Bayes,and phrases,binomial distribution,BinomialConfidenceInterval,confidence,coverage probability,edgeworth expansion,expected length,intervals,jeffreys prior,normal approximation,posterior,bayes},
pages = {101-133},
file = {/Users/k/Zotero/storage/4LCCLVBC/Brown, Cai, DasGupta - 2001 - Interval Estimation for a Binomial Proportion.pdf;/Users/k/Zotero/storage/QMQ7BGH7/Brown, Cai, DasGupta - 2001 - Interval Estimation for a Binomial Proportion.pdf},
pmid = {17566141}
}
@article{Souers2013,
title = {{{ABT}}-199, a Potent and Selective {{BCL}}-2 Inhibitor, Achieves Antitumor Activity While Sparing Platelets.},
volume = {19},
issn = {1546-170X},
doi = {10.1038/nm.3048},
abstract = {Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are key regulators of the apoptotic process. This family comprises proapoptotic and prosurvival proteins, and shifting the balance toward the latter is an established mechanism whereby cancer cells evade apoptosis. The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers. However, concomitant on-target thrombocytopenia caused by BCL-X(L) inhibition limits the efficacy achievable with this agent. Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199. This compound inhibits the growth of BCL-2-dependent tumors in vivo and spares human platelets. A single dose of ABT-199 in three patients with refractory chronic lymphocytic leukemia resulted in tumor lysis within 24 h. These data indicate that selective pharmacological inhibition of BCL-2 shows promise for the treatment of BCL-2-dependent hematological cancers.},
number = {2},
journal = {Nature medicine},
author = {Souers, Andrew J and Leverson, Joel D and Boghaert, Erwin R and Ackler, Scott L and Catron, Nathaniel D and Chen, Jun and Dayton, Brian D and Ding, Hong and Enschede, Sari H and Fairbrother, Wayne J and Huang, David C S and Hymowitz, Sarah G and Jin, Sha and Khaw, Seong Lin and Kovar, Peter J and Lam, Lloyd T and Lee, Jackie and Maecker, Heather L and Marsh, Kennan C and Mason, Kylie D and Mitten, Michael J and Nimmer, Paul M and Oleksijew, Anatol and Park, Chang H and Park, Cheol-Min and Phillips, Darren C and Roberts, Andrew W and Sampath, Deepak and Seymour, John F and Smith, Morey L and Sullivan, Gerard M and Tahir, Stephen K and Tse, Chris and Wendt, Michael D and Xiao, Yu and Xue, John C and Zhang, Haichao and a Humerickhouse, Rod and Rosenberg, Saul H and Elmore, Steven W},
year = {2013},
keywords = {Female,Humans,CLL,Antineoplastic Agents,Antineoplastic Agents: therapeutic use,BCL-2,ABT199,Aniline Compounds,Aniline Compounds: pharmacology,Animals,Antineoplastic Agents: pharmacology,Apoptosis,Apoptosis: drug effects,bcl-X Protein,bcl-X Protein: antagonists \& inhibitors,Bicyclo Compounds,Blood Platelets,Blood Platelets: drug effects,Cell Survival,Cell Survival: drug effects,Dogs,HeLa Cells,Hematologic Neoplasms,Hematologic Neoplasms: drug therapy,Heterocyclic,Heterocyclic: pharmacology,Mice,Proto-Oncogene Proteins c-bcl-2,Proto-Oncogene Proteins c-bcl-2: antagonists \& inh,Proto-Oncogene Proteins c-bcl-2: chemistry,SCID,Sulfonamides,Sulfonamides: pharmacology,Tumor Burden,Xenograft Model Antitumor Assays},
pages = {202-8},
file = {/Users/k/Zotero/storage/BUSXNDBJ/Souers et al. - 2013 - ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.pdf;/Users/k/Zotero/storage/X5KSC5M9/Souers et al. - 2013 - ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.pdf},
pmid = {23291630}
}
@article{Schnipper2015,
title = {American {{Society}} of {{Clinical Oncology Statement}}: {{A Conceptual Framework}} to {{Assess}} the {{Value}} of {{Cancer Treatment Options}}},
issn = {0732-183X},
doi = {10.1200/JCO.2015.61.6706},
journal = {Journal of Clinical Oncology},
author = {Schnipper, L. E. and Davidson, N. E. and Wollins, D. S. and Tyne, C. and Blayney, D. W. and Blum, D. and Dicker, a. P. and a. Ganz, P. and Hoverman, J. R. and Langdon, R. and Lyman, G. H. and Meropol, N. J. and Mulvey, T. and Newcomer, L. and Peppercorn, J. and Polite, B. and Raghavan, D. and Rossi, G. and Saltz, L. and Schrag, D. and Smith, T. J. and Yu, P. P. and a. Hudis, C. and Schilsky, R. L.},
year = {2015},
keywords = {ASCO,ValueInCancer},
file = {/Users/k/Zotero/storage/JSUZ8CJN/Schnipper et al. - 2015 - American Society of Clinical Oncology Statement A Conceptual Framework to Assess the Value of Cancer Treatment.pdf;/Users/k/Zotero/storage/PEPQ48GD/Schnipper et al. - 2015 - American Society of Clinical Oncology Statement A Conceptual Framework to Assess the Value of Cancer Treatment.pdf}
}
@article{Wadhwa2012,
title = {Factors Affecting Duration of Survival after Onset of Blastic Transformation of Chronic Myeloid Leukemia {{Factors}} Affecting Duration of Survival after Onset of Blastic Transformation of Chronic Myeloid Leukemia},
volume = {99},
doi = {10.1182/blood.V99.7.2304},
number = {7},
author = {Wadhwa, Jyoti and Szydlo, Richard M and Apperley, Jane F and Chase, Andrew and Bua, Marco and Marin, David and Kanfer, Edward and Goldman, John M and Olavarria, Eduardo},
year = {2012},
keywords = {CML},
pages = {2304-2309},
file = {/Users/k/Zotero/storage/BUGECS3R/Wadhwa et al. - 2012 - Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia Factors.pdf;/Users/k/Zotero/storage/TC4IHEPH/Wadhwa et al. - 2012 - Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia Factors.pdf}
}
@article{Cortes2012,
title = {Ponatinib in Refractory {{Philadelphia}} Chromosome-Positive Leukemias.},
volume = {367},
issn = {1533-4406},
doi = {10.1056/NEJMoa1205127},
abstract = {BACKGROUND: Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain. Ponatinib (AP24534) is a potent oral tyrosine kinase inhibitor that blocks native and mutated BCR-ABL, including the gatekeeper mutant T315I, which is uniformly resistant to tyrosine kinase inhibitors.$\backslash$n$\backslash$nMETHODS: In this phase 1 dose-escalation study, we enrolled 81 patients with resistant hematologic cancers, including 60 with CML and 5 with Ph-positive ALL. Ponatinib was administered once daily at doses ranging from 2 to 60 mg. Median follow-up was 56 weeks (range, 2 to 140).$\backslash$n$\backslash$nRESULTS: Dose-limiting toxic effects included elevated lipase or amylase levels and pancreatitis. Common adverse events were rash, myelosuppression, and constitutional symptoms. Among Ph-positive patients, 91\% had received two or more approved tyrosine kinase inhibitors, and 51\% had received all three approved tyrosine kinase inhibitors. Of 43 patients with chronic-phase CML, 98\% had a complete hematologic response, 72\% had a major cytogenetic response, and 44\% had a major molecular response. Of 12 patients who had chronic-phase CML with the T315I mutation, 100\% had a complete hematologic response and 92\% had a major cytogenetic response. Of 13 patients with chronic-phase CML without detectable mutations, 100\% had a complete hematologic response and 62\% had a major cytogenetic response. Responses among patients with chronic-phase CML were durable. Of 22 patients with accelerated-phase or blast-phase CML or Ph-positive ALL, 36\% had a major hematologic response and 32\% had a major cytogenetic response.$\backslash$n$\backslash$nCONCLUSIONS: Ponatinib was highly active in heavily pretreated patients with Ph-positive leukemias with resistance to tyrosine kinase inhibitors, including patients with the BCR-ABL T315I mutation, other mutations, or no mutations. (Funded by Ariad Pharmaceuticals and others; ClinicalTrials.gov number, NCT00660920.).},
number = {22},
journal = {The New England journal of medicine},
author = {Cortes, Jorge E and Kantarjian, Hagop and Shah, Neil P and Bixby, Dale and Mauro, Michael J and Flinn, Ian and O'Hare, Thomas and Hu, Simin and Narasimhan, Narayana I and Rivera, Victor M and Clackson, Tim and Turner, Christopher D and Haluska, Frank G and Druker, Brian J and Deininger, Michael W N and Talpaz, Moshe},
year = {2012},
keywords = {Adult,Female,Humans,CML,Follow-Up Studies,Fusion Proteins,Leukemia,Middle Aged,Antineoplastic Agents,bcr-abl,BCR-ABL Positive,BCR-ABL Positive:,Chronic,Myelogenous,Male,Antineoplastic Agents: administration \& dosage,Antineoplastic Agents: adverse effects,Dose-Response Relationship,Drug,80 and over,Aged,Imidazoles,Imidazoles: adverse effects,Ponatinib,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Precursor Cell Lymphoblastic Leukemia-Lymphoma: dr,Pyridazines,Pyridazines: adverse effects,Amylases,Amylases: blood,Antineoplastic Agents: chemistry,bcr-abl: antagonists \& inhibitors,bcr-abl: genetics,Drug Resistance,Imidazoles: administration \& dosage,Imidazoles: chemistry,Lipase,Lipase: blood,Mutation,Neoplasm,Pancreatitis,Pancreatitis: chemically induced,Protein-Tyrosine Kinases,Protein-Tyrosine Kinases: antagonists \& inhibitors,Protein-Tyrosine Kinases: genetics,Pyridazines: administration \& dosage,Pyridazines: chemistry,Structure-Activity Relationship},
pages = {2075-88},
file = {/Users/k/Zotero/storage/3QVZ97PP/Cortes et al. - 2012 - Ponatinib in refractory Philadelphia chromosome-positive leukemias.pdf;/Users/k/Zotero/storage/5JNARNCW/Cortes et al. - 2012 - Ponatinib in refractory Philadelphia chromosome-positive leukemias.pdf;/Users/k/Zotero/storage/M9HGXIJI/Cortes et al. - 2012 - Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias.pdf},
pmid = {23190221}
}
@article{Cortes2013,
title = {A Phase 2 Trial of Ponatinib in {{Philadelphia}} Chromosome-Positive Leukemias.},
volume = {369},
issn = {1533-4406},
doi = {10.1056/NEJMoa1306494},
abstract = {BACKGROUND: Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor-refractory threonine-to-isoleucine mutation at position 315 (T315I). We conducted a phase 2 trial of ponatinib in patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL). METHODS: We enrolled 449 heavily pretreated patients who had CML or Ph-positive ALL with resistance to or unacceptable side effects from dasatinib or nilotinib or who had the BCR-ABL T315I mutation. Ponatinib was administered at an initial dose of 45 mg once daily. The median follow-up was 15 months. RESULTS: Among 267 patients with chronic-phase CML, 56\% had a major cytogenetic response (51\% of patients with resistance to or unacceptable side effects from dasatinib or nilotinib and 70\% of patients with the T315I mutation), 46\% had a complete cytogenetic response (40\% and 66\% in the two subgroups, respectively), and 34\% had a major molecular response (27\% and 56\% in the two subgroups, respectively). Responses were observed regardless of the baseline BCR-ABL kinase domain mutation status and were durable; the estimated rate of a sustained major cytogenetic response of at least 12 months was 91\%. No single BCR-ABL mutation conferring resistance to ponatinib was detected. Among 83 patients with accelerated-phase CML, 55\% had a major hematologic response and 39\% had a major cytogenetic response. Among 62 patients with blast-phase CML, 31\% had a major hematologic response and 23\% had a major cytogenetic response. Among 32 patients with Ph-positive ALL, 41\% had a major hematologic response and 47\% had a major cytogenetic response. Common adverse events were thrombocytopenia (in 37\% of patients), rash (in 34\%), dry skin (in 32\%), and abdominal pain (in 22\%). Serious arterial thrombotic events were observed in 9\% of patients; these events were considered to be treatment-related in 3\%. A total of 12\% of patients discontinued treatment because of an adverse event. CONCLUSIONS: Ponatinib had significant antileukemic activity across categories of disease stage and mutation status. (Funded by Ariad Pharmaceuticals and others; PACE ClinicalTrials.gov number, NCT01207440 .).},
number = {19},
journal = {The New England journal of medicine},
author = {Cortes, J E and Kim, D-W and {Pinilla-Ibarz}, J and {le Coutre}, P and Paquette, R and Chuah, C and Nicolini, F E and Apperley, J F and Khoury, H J and Talpaz, M and DiPersio, J and DeAngelo, D J and Abruzzese, E and Rea, D and Baccarani, M and M\"uller, M C and {Gambacorti-Passerini}, C and Wong, S and Lustgarten, S and Rivera, V M and Clackson, T and Turner, C D and Haluska, F G and Guilhot, F and Deininger, M W and Hochhaus, A and Hughes, T and Goldman, J M and Shah, N P and Kantarjian, H},
year = {2013},
keywords = {Adult,Female,Humans,CML,Leukemia,Middle Aged,BCR-ABL Positive,Chronic,Myelogenous,Male,80 and over,Adolescent,Aged,BCR-ABL Positive: drug therapy,Imidazoles,Imidazoles: adverse effects,Imidazoles: therapeutic use,Ponatinib,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Precursor Cell Lymphoblastic Leukemia-Lymphoma: dr,Protein Kinase Inhibitors,Protein Kinase Inhibitors: adverse effects,Protein Kinase Inhibitors: therapeutic use,Pyridazines,Pyridazines: adverse effects,Pyridazines: therapeutic use,Thrombocytopenia,Thrombocytopenia: chemically induced,Thrombosis,Thrombosis: chemically induced,Young Adult},
pages = {1783-96},
file = {/Users/k/Zotero/storage/FBZDBEAV/Cortes et al. - 2013 - A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.pdf;/Users/k/Zotero/storage/SUKNEKDA/Cortes et al. - 2013 - A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias.pdf},
pmid = {24180494}
}
@book{Cheung2011,
address = {New York},
title = {Dose {{Finding}} by the {{Continual Reassessment Method}}},
publisher = {{Chapman \& Hall / CRC Press}},
author = {Cheung, Ying Kuen},
year = {2011},
keywords = {DoseFinding,CRM},
file = {/Users/k/Zotero/storage/SEF8W28V/Cheung - 2011 - Dose Finding by the Continual Reassessment Method.pdf}
}
@article{AhnOptimal,
title = {Optimal {{Biological Dose}} for {{Molecularly}}-{{Targeted Therapies}}},
journal = {Wiley StatsRef: Statistics Reference Online},
author = {Ahn, Chul and Kang, Seung-Ho and Xie, Yang}
}
@article{Babb1998,
title = {Cancer Phase {{I}} Clinical Trials: {{Efficient}} Dose Escalation with Overdose Control},
volume = {17},
issn = {02776715},
doi = {10.1002/(SICI)1097-0258(19980530)17:10<1103::AID-SIM793>3.0.CO;2-9},
abstract = {We describe an adaptive dose escalation scheme for use in cancer phase I clinical trials. The method is fully adaptive, makes use of all the information available at the time of each dose assignment, and directly addresses the ethical need to control the probability of overdosing. It is designed to approach the maximum tolerated dose as fast as possible subject to the constraint that the predicted proportion of patients who receive an overdose does not exceed a specified value. We conducted simulations to compare the proposed method with four up-and-down designs, two stochastic approximation methods, and with a variant of the continual reassessment method. The results showed the proposed method effective as a means to control the frequency of overdosing. Relative to the continual reassessment method, our scheme overdosed a smaller proportion of patients, exhibited fewer toxicities and estimated the maximum tolerated dose with comparable accuracy. When compared to the non-parametric schemes, our method treated fewer patients at either subtherapeutic or severely toxic dose levels, treated more patients at optimal dose levels and estimated the maximum tolerated dose with smaller average bias and mean squared error. Hence, the proposed method is promising alternative to currently used cancer phase I clinical trial designs.},
number = {10},
journal = {Statistics in Medicine},
author = {Babb, James and Rogatko, Andr\'e and Zacks, Shelemyahu},
year = {1998},
keywords = {DoseFinding},
pages = {1103-1120},
file = {/Users/k/Zotero/storage/ATN8HW28/Babb, Rogatko, Zacks - 1998 - Cancer phase I clinical trials Efficient dose escalation with overdose control.pdf;/Users/k/Zotero/storage/MD9WA7WM/Babb, Rogatko, Zacks - 1998 - Cancer phase I clinical trials Efficient dose escalation with overdose control.pdf},
pmid = {9618772}
}
@article{Ji2010,
title = {A Modified Toxicity Probability Interval Method for Dose-Finding Trials.},
volume = {7},
issn = {1740-7745},
doi = {10.1177/1740774510382799},
abstract = {Building on earlier work, the toxicity probability interval (TPI) method, we present a modified TPI (mTPI) design that is calibration-free for phase I trials.},
number = {6},
journal = {Clinical trials (London, England)},
author = {Ji, Yuan and Liu, Ping and Li, Yisheng and Bekele, B Nebiyou},
year = {2010},
keywords = {DoseFinding},
pages = {653-663},
file = {/Users/k/Zotero/storage/SN8PGGPD/Ji et al. - 2010 - A modified toxicity probability interval method for dose-finding trials.pdf},
pmid = {20935021}
}
@article{OQuigley2001,
title = {Dose-Finding Designs for {{HIV}} Studies.},
volume = {57},
issn = {0006341X},
doi = {10.1111/j.0006-341X.2001.01018.x},
abstract = {We present a class of simple designs that can be used in early dose-finding studies in HIV. Such designs, in contrast with Phase I designs in cancer, have a lot of the Phase II flavor about them. Information on efficacy is obtained during the trial and is as important as that relating to toxicity. The designs proposed here sequentially incorporate the information obtained on viral reduction. Initial doses are given from some fixed range of dose regimens. The doses are ordered in terms of their toxic potential. At any dose, a patient can have one of three outcomes: inability to take the treatment (toxicity), ability to take the treatment but insufficient reduction in viral load (viral failure), and ability to take the treatment as well as a sufficient reduction of viral load (success). A clear goal for some class of designs would be the identification of the dose leading to the greatest percentage of successes. Under certain assumptions, which we identify and discuss, we can obtain efficient designs for this task. Under weaker, sometimes more realistic assumptions, we can still obtain designs that have good operating characteristics in identifying a level, if such a level exists, having some given or greater success rate. In the absence of such a level, the designs will come to an early closure, indicating the ineffectiveness of the new treatment.},
number = {4},
journal = {Biometrics},
author = {O'Quigley, J and Hughes, M D and Fenton, T},
year = {2001},
keywords = {DoseFinding,clinical trials,Continual reassessment method,toxicity,EfficacyToxicity,phase ii trial,phase i trial,dose-finding studies,dose escalation,efficacy studies,hiv,continual reassessment method},
pages = {1018-1029},
file = {/Users/k/Zotero/storage/US5P9SXJ/O'Quigley, Hughes, Fenton - 2001 - Dose-finding designs for HIV studies.pdf},
pmid = {11764240}
}
@article{Iasonos2008,
title = {A Comprehensive Comparison of the Continual Reassessment Method to the Standard 3 + 3 Dose Escalation Scheme in {{Phase I}} Dose-Finding Studies.},
volume = {5},
issn = {1740-7745},
doi = {10.1177/1740774508096474},
abstract = {BACKGROUND: An extensive literature has covered the statistical properties of the Continual Reassessment Method (CRM) and the modifications of this method. While there are some applications of CRM designs in recent Phase I trials, the standard method (SM) of escalating doses after three patients with an option for an additional three patients SM remains very popular, mainly due to its simplicity. From a practical perspective, clinicians are interested in designs that can estimate the MTD using fewer patients for a fixed number of doses, or can test more dose levels for a given sample size. PURPOSE: This article compares CRM-based methods with the SM in terms of the number of patients needed to reach the MTD, total sample size required, and trial duration. METHODS: The comparisons are performed under two alternative schemes: a fixed or a varying sample approach with the implementation of a stopping rule. The stopping rule halts the trial if the confidence interval around the MTD is within a pre-specified bound. Our simulations evaluated several CRM-based methods under different scenarios by varying the number of dose levels from five to eight and the location of the true MTD. RESULTS: CRM and SM are comparable in terms of how fast they reach the MTD and the total sample size required when testing a limited number of dose levels ($<$or=5), but as the number of dose levels increases, CRM reaches the MTD in fewer patients when used with a fixed sample of 20 patients. However, a sample size of 20-25 patients is not sufficient to achieve a narrow precision around the estimated toxicity rate at the MTD. LIMITATIONS: We focused on methods with practical design features that are of interest to clinicians. However, there are several alternative CRM-based designs that are not investigated in this manuscript, and hence our results are not generalizable to other designs. CONCLUSIONS: We show that CRM-based methods are an improvement over the SM in terms of accuracy and optimal dose allocation in almost all cases, except when the true dose is among the lower levels.},
number = {5},
journal = {Clinical trials (London, England)},
author = {Iasonos, Alexia and Wilton, Andrew S and Riedel, Elyn R and Seshan, Venkatraman E and Spriggs, David R},
year = {2008},
keywords = {README},
pages = {465-477},
file = {/Users/k/Zotero/storage/9GD65VQK/Iasonos et al. - 2008 - A comprehensive comparison of the continual reassessment method to the standard 3 3 dose escalation scheme in P.pdf},
pmid = {18827039}
}
@article{Garrett-Mayer2006,
title = {The Continual Reassessment Method for Dose-Finding Studies: A Tutorial.},
volume = {3},
issn = {17407745},
doi = {10.1191/1740774506cn134oa},
abstract = {The Continual Reassessment Method (CRM), along with other adaptive dose-finding study designs, has gained popularity since its proposal by O'Quigley. Several of the reasons it has been embraced by clinical trialists is that it tends to incur fewer toxic events, and more accurately estimate the maximum tolerated dose as compared to the standard Phase I dose escalation designs. Many variations have been published and discussed in the statistical literature, but there has not been as much practical advice for choosing design parameters and implementing the CRM. As a result, the CRM has not been as widely utilized as it could be for dose-finding studies. The goal of this paper is to provide a tutorial for those unfamiliar with the CRM who are either statisticians considering using the CRM for the first time, or investigators with some statistical background. This paper presents the original CRM, and then some of its modified versions. It also explains the specifications that define a CRM design, along with simulated examples of CRMs and standard designs, for illustration.},
number = {1},
journal = {Clinical trials (London, England)},
author = {{Garrett-Mayer}, Elizabeth},
year = {2006},
keywords = {DoseFinding,CRM},
pages = {57-71},
file = {/Users/k/Zotero/storage/FANYZIHP/Garrett-Mayer - 2006 - The continual reassessment method for dose-finding studies a tutorial.pdf},
pmid = {16539090}
}
@article{Altman2006,
title = {Statistics {{Notes}} 52: {{The}} Cost of Dichotomising Continuous Variables},
volume = {332},
issn = {1468-5833},
doi = {10.1136/bmj.332.7549.1080},
abstract = {\#statistics},
number = {7549},
journal = {British Medical Journal},
author = {Altman, Douglas G and Royston, Patrick},
year = {2006},
keywords = {Anti-dichotomisation,Data Interpretation,Statistical,Regression Analysis},
pages = {1080},
file = {/Users/k/Zotero/storage/CKUEHX7B/Altman, Royston - 2006 - Statistics Notes 52 The cost of dichotomising continuous variables.pdf},
pmid = {16675816}
}
@article{Gajewsji2008,
title = {Predicting Accrual in Clinical Trials with {{Bayesian}} Posterior Predictive Distributions},
volume = {27},
abstract = {Although sample size calculations have become an important element in the design of research projects, such methods for studies involving current status data are scarce. Here, we propose a method for calculating power and sample size for studies using current status data. This method is based on a Weibull survival model for a two-group comparison. The Weibull model allows the investigator to specify a group difference in terms of a hazards ratio or a failure time ratio. We consider exponential, Weibull and uniformly distributed censoring distributions. We base our power calculations on a parametric approach with the Wald test because it is easy for medical investigators to conceptualize and specify the required input variables. As expected, studies with current status data have substantially less power than studies with the usual right-censored failure time data. Our simulation results demonstrate the merits of these proposed power calculations.},
journal = {Statistics in medicine},
author = {Gajewski, Byron J. and Simon, Stephen D. and Carlson, Susan E.},
year = {2008},
keywords = {Accrual,bayesian,sample size,exponential,inverse gamma,prior elicitation},
pages = {2328-2340},
file = {/Users/k/Zotero/storage/MDNEHZMW/Gajewski, Simon, Carlson - 2008 - Predicting accrual in clinical trials with Bayesian posterior predictive distributions.pdf},
pmid = {19455509}
}